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ABSTRACT OF DISSERTATION 
 
 
 
 
MECHANISTIC BASIS FOR ATRIAL AND VENTRICULAR ARRHYTHMIAS 
CAUSED BY KCNQ1 MUTATIONS 
  
 Cardiac arrhythmias are caused by a disruption of the normal initiation or 
propagation of electrical impulses in the heart. Hundreds of mutations in genes 
encoding ion channels or ion channel regulatory proteins are linked to congenital 
arrhythmia syndromes that increase the risk for sudden cardiac death. This 
dissertation focuses on how mutations in a gene (KCNQ1) that encodes a 
voltage-gated K+ ion channel (Kv7.1) can disrupt proper channel function and 
lead to abnormal repolarization of atrial and ventricular cardiomyocytes.  
 
 In the heart, Kv7.1 coassembles with a regulatory protein to conduct the 
slowly activating delayed rectifier K+ current (IKs). Loss-of-function KCNQ1 
mutations are linked to type 1 long QT syndrome (LQT1), and typically decrease 
IKs, which can lead to ventricular action potential (AP) prolongation. In patients, 
LQT1 is often characterized by an abnormally long corrected QT (QTc) interval 
on an electrocardiogram (ECG), and increases the risk for polymorphic 
ventricular tachycardias. 
 
 KCNQ1 mutations are also linked to atrial fibrillation (AF), but cause a 
gain-of-function phenotype that increases IKs. Surprisingly, patients diagnosed 
with both LQT1 and AF are increasingly identified as genotype positive for a 
KCNQ1 mutation. The first aim of this dissertation was to determine a unique 
functional phenotype of KCNQ1 mutations linked to both arrhythmia syndromes 
by functional analysis via the whole-cell patch clamp technique in HEK293 cells.  
 
 A proportion of patients with LQT1-linked KCNQ1 mutations do not have 
abnormal QTc prolongation known as latent LQT1. Interestingly, exercise can 
reveal abnormal QTc prolongation in these patients. During exercise, β-
adrenergic activation stimulates PKA to phosphorylate Kv7.1, causing an 
increase in IKs to prevent ventricular AP prolongation. Therefore, the second aim 
of this dissertation was to determine a molecular mechanism of latent LQT1 
through functional analyses in HEK293 cells while incorporating pharmacological 
 
and phosphomimetic approaches to study PKA regulation of mutant Kv7.1 
channels. 
   
 The findings in this dissertation provide new insight into how KCNQ1 
mutations disrupt the function of Kv7.1 in a basal condition or during β-adrenergic 
activation. Also, this dissertation suggests these approaches will improve patient 
management by identifying mutation specific risk factors for patients with KCNQ1 
mutations. 
 
KEYWORDS: congenital arrhythmia syndromes, voltage-gated potassium ion 
channels, cardiac action potential, long QT syndrome, atrial fibrillation 
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Chapter 1 
Introduction 
 
1.1 Congenital arrhythmia syndromes 
 Each year, thousands of people die from sudden cardiac death due to cardiac 
arrhythmias.1 Most cases are due to underlying conditions such as coronary 
artery disease or structural remodeling of the heart, but a proportion is caused by 
defects in cardiac electrophysiology. Some patients with arrhythmias primarily 
due to electrophysiological issues have a genetic predisposition, and a common 
cause is an inherited or congenital arrhythmia syndrome. Therefore, identifying 
genetic mutations in families at risk can provide a link between clinical 
phenotypes and molecular mechanisms. Mutations associated with congenital 
arrhythmia syndromes are often identified in ion channel genes, and they 
typically disrupt ion channel function to disorder the normal electrophysiology of 
the heart. Understanding the molecular mechanism and functional phenotypes of 
mutations linked to congenital arrhythmias can provide insight into clinical 
diagnosis and therapeutic intervention of current and future generations.  
 In this dissertation, I focus on one cardiac ion channel macromolecular 
complex, and show how single mutations are capable of altering protein function, 
the cardiac action potential (AP), and arrhythmia susceptibility to predispose 
patients to multiple clinical phenotypes. My work demonstrates the importance of 
proper ion channel function in the heart, and how disrupting the function of one 
protein can be detrimental to one’s well being.  
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 In this chapter, I briefly introduce the different types of cardiac ion channels 
and their roles in generating ionic currents that shape the cardiac AP. I then, 
focus on the voltage-gated K+ ion channel, Kv7.1, which conducts the slowly 
activating component of the delayed rectifier K+ current (IKs) important for normal 
repolarization. Given the focus on Kv7.1, the remainder of this chapter discusses 
mutations within the Kv7.1 gene (KCNQ1) that associate with different clinical 
phenotypes and how different mutations in Kv7.1 might lead to an increased risk 
for atrial and/or ventricular arrhythmias.  
 
1.2 Electrical properties of the heart and the cardiac AP 
1.2.1 Electrical properties of the heart 
 The coordinated contractions of the human heart are controlled by continuous 
electrical signals that spontaneously originate in the pacemaker cells of the 
sinoatrial node.2 The electrical signals generate an AP in individual cells that can 
propagate to adjacent cells that are electrically coupled by gap junction connexin 
hemichannels.3 APs are a direct result from the opening and closing of ion 
channels. Different regions in the heart express different ion channels, which 
alters the shape of the AP waveform in specific regions throughout the cardiac 
tissue and promotes the unidirectional propagation of the electrical waveform 
electromechanically coupling the heart.4-6 From the sinoatrial node, the electrical 
waveform propagates through the atrial tissue to the atrioventricular node, and it 
is then conducted through the bundles of His towards the apex of the heart. 
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Lastly, the electrical waveform propagates throughout the ventricular tissue via 
the Purkinje fibers coordinating excitation-contraction coupling.  
 
1.2.2 Cardiac ion channels and the cardiac AP 
 Ion channels play an important role in shaping the AP in cardiomyocytes. Ion 
channels are transmembrane proteins that allow movement of charged ions (K+, 
Ca2+, Na+) across the plasma membrane down their electrochemical gradient 
through a selective pore domain.7 Many ion channels expressed in 
cardiomyocytes are voltage-gated; whereas, they have a voltage-sensing domain 
consisting of conserved positively charged amino acid residues in the fourth 
transmembrane segment (S4) that moves in response to changes in membrane 
potential to open and close the pore.7-9 The opening and closing of ion channels 
alter the membrane permeability and membrane potential to generate an AP.  
  The most common types of voltage-gated ion channels are voltage-gated 
Na+ (Nav), voltage-gated Ca2+ (Cav), and voltage-gated K+ (Kv) channels. 
Generally, the rapid upstroke or depolarization of the membrane in atrial and 
ventricular myocytes (phase 0) is due to the opening or activation of Nav 
channels.10 Rapid inactivation of Nav channels and the activation of transient 
outward Kv channels generate the “notch” phase (phase 1), which is a partial 
repolarization of the membrane.11, 12 Cav channels also activate due to 
depolarization, but the time course of activation is slower than Nav channels. 
During the plateau phase, L-type Cav channels conduct inward Ca2+ current 
(ICa,L) that is important for calcium-induced-calcium release that controls the 
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excitation-contraction coupling of cardiomyocytes.13 The delayed rectifier Kv 
channels are the slowest to activate, and activate during the plateau phase to 
conduct outward K+ currents (IK). During the plateau phase, the AP waveforms of 
cardiomyocytes maintain depolarized for hundreds of milliseconds because of a 
balance between inward ICa,L and outward IK. As Cav channels inactivate, the 
outward IK predominate, and repolarization (phase 3) occurs.  
 The delayed rectifier Kv channels are comprised of two Kv channels (Kv7.1 
and Kv11.1) that conduct distinct components: the slowly and rapidly activating 
delayed rectifier K+ currents (IKs and IKr, respectively).14 These channels differ in 
their time- and voltage-dependent functions as well as drug sensitivities and 
regional distribution. In addition to the delayed rectifier Kv channels, a third K+-
selective ion channel contributes to the repolarization phase and is the voltage-
independent inward-rectifying K+-channel (Kir). It is most permeable at negative 
membrane potentials and contributes to the resting membrane potential (phase 
4) of the AP waveforms.15, 16  
 The distinct waveforms of the atrial and ventricular AP are crucial for the 
propagation of electrical signaling and excitation-contraction coupling of the heart. 
This requires the proper functioning and regional distribution of many different ion 
channels (Nav, Cav, Kv, Kir, and more). Interestingly, mutations in the ion 
channels encoding genes are linked to congenital arrhythmia syndromes and 
disrupt normal ion channel function leading to abnormalities of AP waveforms.  
 My entire dissertation project focuses on how mutations associated to a 
delayed rectifier Kv channel (Kv7.1) can disrupt the properties of IKs and thus, 
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repolarization of the atrial and ventricular AP waveforms. Mutations within the 
gene encoding Kv7.1 (KCNQ1) are linked to the most common congenital 
arrhythmia syndrome, type 1 long QT syndrome. In the following sections, I 
explain the history of how Kv7.1 was originally linked to arrhythmias, how Kv7.1 
contributes to the atrial and ventricular AP, and how Kv7.1 dysfunction 
contributes to atrial and ventricular congenital arrhythmia syndromes. 
 
1.3 KCNQ1 cloning, protein expression, and Kv7.1’s role in the human heart  
 In 1996, positional cloning identified KCNQ1 to chromosome 11p15.5 as the 
causative gene responsible for the most common congenital arrhythmia 
syndrome, type 1 long QT syndrome (LQT1, which will be discussed in detail in 
section 1.4).17 KCNQ1 encodes the pore forming Kv7.1 α-subunit and is a 
member of a family of slow delayed rectifier K+ channels that includes Kv7.2-
7.5.18 Similar to other voltage-gated K+ α-subunits, Kv7.1 consists of six α-helical 
transmembrane segments (S1-S6), intracellular amino- (N-) and carboxyl- (C-) 
termini, and is functional as a tetrameric protein embedded in the plasma 
membrane (Figure 1.1).7 The transmembrane segments S1-S4 comprise the 
voltage-sensing domain, and S5-S6 form the K+-selective pore. Positively 
charged amino acid residues are highly conserved in S4 among voltage-gated K+ 
channels, while negatively charges amino acid residues are conserved within S1-
S3. These charged residues maintain important electrostatic interactions 
between each other in order to stabilize Kv7.1 in a state-dependent manner and 
enable Kv7.1 to respond to changes in transmembrane potentials.8 
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 In humans, Kv7.1 is expressed in a wide range of cell types including 
cardiomyocytes and a variety of epithelial cells (lung, stomach, pancreas, 
cochlea, intestine, and kidneys), but Kv7.1 is the only member of the Kv7.x family 
not identified in neuronal tissue.19, 20 Kv7.1 has different tissue-specific functions 
as it may contribute to repolarization of the cardiac AP or transmembrane 
transport of water and salts in epithelial tissues.21-25  Based on location and 
function, Kv7.1 forms different heteromeric channel complexes with an 
assortment of KCNE β-subunits (KCNE1-5), and each β-subunit interact with 
Kv7.1 to generate unique functional phenotypes.26-28 For instance, coexpression 
of wild-type Kv7.1 (WT-Kv7.1) with KCNE1 in a heterologous system results in 
large increases in macroscopic Kv7.1 current (IKv7.1), the time course of activation 
or deactivation are slowed, and Kv7.1 inactivation is almost completely 
suppressed (Figure 1.1).24, 25 Coexpression of WT-Kv7.1 with either KCNE2 or 
KCNE3 generates constitutive (increases the open probability at resting or 
negative membrane potentials) IKv7.1; whereas, IKv7.1 amplitude is much larger 
when expressed with KCNE3 than cells expressing KCNE2.29, 30 When 
expressed with KCNE4, IKv7.1 is largely reduced, and KCNE5 shifts voltage 
dependence of activation positively while slowing the time course of activation of 
Kv7.1 similar to KCNE1.31 
 In the heart, Kv7.1 most commonly coassembles with KCNE1 to conduct IKs, 
which is critical for the repolarization phase of the atrial and ventricular AP 
(heterologous expression of Kv7.1 and KCNE1 yields IKv7.1 that resembles native 
IKs).24, 25 The cardiac AP duration is characterized by a long depolarized plateau 
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phase (100s of ms), and the duration of the plateau is influenced by the balance 
of inward depolarizing or outward repolarizing ionic currents.32 IKs, along with two 
other K+-selective currents (IKr and IK1) constitutes the “repolarization reserve” of 
the cardiac AP.33, 34 All three currents are important for controlling the cardiac AP 
duration and the resting membrane potential. Mutations within the three genes 
encoding the pore-forming α-subunits of these K+-selective currents, KCNQ1, 
KCNH2, and KCNJ2, can disrupt IKs, IKr, or IK1 and are all linked to subtypes of 
congenital long QT syndrome, LQTS (LQT1, LQT2, and LQT7, respectively).33-37 
 
1.4 Congenital long QT syndrome and KCNQ1 
1.4.1 Congenital long QT syndrome 
 Congenital LQTS is a disease affecting cardiomyocyte repolarization with a 
prevalence of ~1 in 2500 patients and is linked to thirteen genes encoding ion 
channels or regulatory counterparts (LQT1-LQT13, see Table 1.1 for overview of 
genes linked to LQTS).38, 39 LQTS patients are typically characterized by 
borderline to prolonged resting corrected QT intervals (QTc intervals) on an 
electrocardiogram (ECG), and have an increased risk for life-threatening events 
such as syncope, polymorphic ventricular tachycardias, and sudden cardiac 
death.40-42 Increased risk of sudden cardiac death correlates with a patient’s 
family history, gender, QTc interval, and incidents of syncope or tachycardia.43 
LQTS was originally known as the autosomal dominant Romano-Ward syndrome 
or the more severe form of autosomal recessive Jervell-Lange-Nielsen syndrome 
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that is associated with deafness and compound mutations in KCNQ1 and/or 
KCNE1.44, 45  
 
1.4.2 Diagnosis of long QT syndrome 
 On a surface ECG, the QRS complex corresponds to the upstroke (phase 0) 
of the AP of ventricular tissue and the T wave corresponds to ventricular AP 
repolarization (phase 3). Therefore, the QT interval reflects the duration of the 
ventricular AP. Typically in the clinic, a QT interval is adjusted for an individual’s 
heart rate by various formulas and is reported as the QTc interval.46-48 The most 
commonly used formula to calculate QTc intervals is the Bazett formula: 
QTc = QT/√RR 
Based on this formula, a QTc interval is considered prolonged when it is ≥ 450 
ms for males or ≥ 460 ms for females.49 The diagnosis of LQTS is not as 
straightforward as it would seem because the observation of a patient with a 
prolonged QTc interval does not necessitate an LQTS diagnosis. In order for an 
individual to be diagnosed with LQTS, several criteria must be met using a 
scoring system that ranks a combination of symptoms, family history, and ECG 
observations, called the Schwartz score (see Table 1.2).50 Complicating this 
issue is that there is a high amount of variability in ECG characteristics within 
families and nearly 50% of genotype positive LQTS patients do not have obvious 
ECG abnormalities. Specifically, nearly 40% of LQT1, 20% of LQT2, and 10% of 
LQT3 patients have normal QTc intervals at rest (concealed or latent LQTS).51 
Recent studies show that incorporating exercise treadmill or epinephrine stress 
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testing can expose QTc interval prolongation in patients with latent LQTS, and 
these advanced tools can predict specific subtypes of LQTS such as latent LQT1 
or LQT2.52, 53 The Schwartz score was set up as a system to address the 
probability of having LQTS when genetic testing was not readily available and 
studies suggest that the Schwartz score under predicts the actual number of 
affected patients.54 Therefore, a combination of genetic testing with more 
advanced clinical tools may help increase the accuracy and diagnosis of LQTS. 
 
1.4.3 KCNQ1 and type 1 long QT syndrome 
 One of the most challenging types of LQTS to diagnose is LQT1 because a 
high percentage of patients have a normal resting QTc interval. LQT1 is one of 
the most common types of LQTS that represents > 40% of LQTS cases.38 LQT1 
is linked to hundreds of “loss-of-function” missense KCNQ1 mutations that cause 
LQT1 by decreasing IKs by disrupting Kv7.1 vesicular transport (trafficking), 
protein folding, and/or gating permeation.17 A reduction in IKs reduces the 
repolarization reserve in a ventricular myocyte, which can lead to ventricular AP 
prolongation. A prolonged ventricular AP duration predisposes ventricular 
myocytes to early afterdepolarizations (EAD) or it can cause a dispersion of 
ventricular repolarization in certain regions of the ventricular wall.32, 55 Spatial 
differences in AP duration or repolarization can create ‘pockets’ of inexcitable 
myocardial tissue leading to regions of conduction block that increase the risk for 
electrical impulse reentry.55-57 The resulting EADs or functional reentry can 
culminate into the phenotypic polymorphic ventricular tachycardia (torsades de 
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pointes), and if no intervention follows, these arrhythmias can transform into 
ventricular fibrillation or sudden cardiac death.  
 
1.5 Atrial fibrillation and KCNQ1  
1.5.1 Familial atrial fibrillation 
 Atrial fibrillation (AF) is the most common cardiac arrhythmia syndrome, and 
is characterized by rapid and irregular contractions of the atrial tissue.58 AF 
increases the risk for palpitations, syncope, congestive heart failure, thrombus, 
and stroke, and it is estimated that the lifetime risk for development of AF at age 
> 40 years is one in four people.59, 60 AF usually is secondary to underlying heart 
disease, hypertension, structural or electrical remodeling, or hyperthyroidism. 
However, the disease can present without such symptoms and is known as lone 
AF. Interestingly, ~30% of AF patients have a family history of AF, suggesting a 
genetic predisposition.61  
 Familial AF with autosomal dominant transmission of lone AF was originally 
reported in 1943, but it was not until 2003 that a causative gene was identified.62, 
63 A KCNQ1 mutation was identified through linkage analysis with the autosomal 
dominant form of familial AF in a multigenerational family, and the mutation 
(S140G-Kv7.1) generates a unique functional phenotype. Voltage-clamp analysis 
revealed that cells expressing S140G-Kv7.1 increase the open probability of 
Kv7.1 at negative potentials generating constitutive IKv7.1 at resting membrane 
potentials, and the mutation was defined as a “gain-of-function”.63 Since this 
initial discovery, several other KCNQ1 mutations are suspected to cause familial 
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or sporadic cases of AF. All are considered gain-of-function mutations because 
they generate constitutive IKv7.1 or slow the time course of deactivation.64-66 
Interestingly, mutations in several other genes (KCNE2, KCNE5, and NPPA) that 
regulate the IKs channel complex also associate with AF and studies suggest they 
cause an increase in IKv7.1.66-68 Together, these findings validate the critical roles 
Kv7.1 and IKs have in atrial repolarization. 
 An increase in IKs is expected to shorten the atrial AP duration and reduce the 
effective refractory period.11 Shorter atrial AP durations or reduced effective 
refractory periods increase the excitability of the myocyte. If the effective 
refractory period is shorter than the time it takes a premature electrical stimulus 
to reach this origin, then a subsequent AP can fire and multiple reentry circuits 
can develop if the propagating impulse does not stop.55, 58, 69 Multiple reentry 
circuits increase rapid conduction, disorganize the homogeneity of atrial 
contraction, and serve as the primary drive for AF.69 
 
1.5.2 LQT1, atrial fibrillation, and KCNQ1 
 Recent findings indicate that 2% of LQTS patients have early-onset AF (age < 
50 years) compared to the 0.1% prevalence of AF in the background 
population.70 The majority of patients in this LQTS cohort who had early-onset AF 
have an LQT1 mutation. The observation of one patient with a single mutation 
having LQT1 and AF is perplexing because of the loss- or gain-of-function Kv7.1 
phenotype associated with LQT1- or AF-linked KCNQ1 mutations, respectively. 
Interestingly, nine out of sixteen patients in the family genotype positive for 
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S140G-Kv7.1 have prolonged QTc intervals.63 This is counterintuitive because 
S140G-Kv7.1 is defined as a gain-of-function mutation and is predicted to 
shorten the atrial AP duration.  
 Thus far three other KCNQ1 variants linked to early-onset AF have been 
studied, insIAP54-56-Kv7.1, V141M-Kv7.1, and S209P-Kv7.1.64-66 The insIAP54-
56-Kv7.1 variant is a polymorphism that has been identified in several control 
patients, which suggests it is not a primary cause of AF. Similar to S140G-Kv7.1, 
both V141M-Kv7.1 and S209P-Kv7.1 are only identified in a single family each. 
The lone V141M-Kv7.1 patient was an infant with a short QT interval, and the 
S209P-Kv7.1 family members have normal QTc intervals. Voltage-clamp studies 
with coexpression of WT-Kv7.1 and KCNE1 show that V141M-Kv7.1 and S209P-
Kv7.1 increase IKv7.1 activation at negative membrane potentials, but their effects 
on amplitude of maximally activated IKv7.1 (IMAX) at positive potentials were not 
directly studied. 
 One additional mutation to consider is Q147R-Kv7.1, which was identified in a 
female patient with borderline QTc interval prolongation and persistent AF at the 
age of 83 years.71 The fact that the patient was diagnosed with AF at such a late 
stage in life and no other relatives were genotype positive or had AF warrants 
whether or not this mutation is actually AF-causing. Nonetheless, voltage-clamp 
studies show Q147R-Kv7.1 causes a unique functional phenotype that is 
dependent on coexpression of KCNE β-subunits. Compared to WT-Kv7.1 
expressing cells, cells coexpressing Q147R-Kv7.1 with KCNE1 yield smaller 
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IKv7.1; whereas, larger IKv7.1 was measured from cells coexpressing Q147R-Kv7.1 
and KCNE2.  
 Whether or not there is a unique functional phenotype of Kv7.1 mutant 
channels associated with LQT1 and AF has yet to be determined. Identifying a 
mechanism of how a single mutation can cause chamber specific arrhythmia 
syndromes associated to different functional phenotypes (loss- versus gain-of-
function) would represent a significant breakthrough in understanding the role of 
Kv7.1 in the atrial and ventricular AP. 
 
1.6 Regulation of IKs by PKA phosphorylation and β-Adrenergic receptor 
stimulation 
1.6.1 Adrenergic stimulation in the heart and regulation of the funny current and 
intracellular calcium 
 β-adrenergic receptors are a type of G-protein coupled receptors (GPCR) that 
are typically activated by binding of catecholamines (norepinephrine or 
epinephrine). There are three subtypes of β-adrenergic receptors (β1, β2, and β3), 
and β1-adrenergic receptors are the most common subtype expressed in the 
heart. During sympathetic stimulation, increased cardiac output is a direct result 
of β1-adrenergic receptor activation by binding of norepinephrine or epinephrine. 
Sympathetic stimulation is up regulated during exercise or emotional stress and 
causes increases in the heart rate and contractile forces. As a result, the AP 
duration of ventricular myocytes is shortened to allow proper time for diastolic 
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filling in between successive beats, and this can be observed by alterations of 
the QT interval on an ECG.72  
 β1-adrenergic receptor activation initiates a signaling cascade through Gαs-
proteins that activate adenylate cyclase (AC) to increase intracellular levels of 
cyclic adenosine monophosphate (cAMP).73, 74 cAMP binds to the regulatory 
subunits of protein kinase A (PKA), enabling the catalytic subunits of PKA to 
phosphorylate serine or threonine residues on substrate proteins. PKA function is 
turned off by a negative feedback system; whereas, PKA activates 
phosphodiesterases  (PDE) to degrade cAMP to its inactive form, AMP.75 Many 
ion channels and pumps that control the electrophysiology of the heart are 
therefore regulated indirectly by cAMP because they are substrates for PKA 
phosphorylation. 
 Another important protein regulated directly by cAMP is the hyperpolarization-
activated cyclic nucleotide-gated channel 4 (HCN4) of the pacemaker cells in the 
sinoatrial node. The regulation of HCN4 by cAMP is different from other ion 
channels because it does not require PKA-mediated serine or threonine 
phosphorylation.76 HCN4 channels are activated at negative or hyperpolarizing 
membrane potentials and conduct the funny current (If) that causes steady 
depolarization of pacemaker cells.77 Once a threshold is met, a spontaneous AP 
will fire in the pacemaker cells to initiate the electrical waveform that controls the 
coordinated excitation-contraction coupling of cardiomyocytes. When cAMP 
binds, HCN4 channels activate at more positive potentials, and this increases If 
during diastole. The increase in If decreases the time it takes a pacemaker cell to 
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reach threshold to generate a spontaneous AP, and thus, increases the heart 
rate.76, 78 
 β1-adrenergic receptor activation also regulates the control of Ca2+ transients 
and contractility of cardiomyocytes. Downstream of cAMP, PKA phosphorylates 
numerous proteins including L-type Cav channels, ryanodine receptors, and 
phospholamben to increase the amount of Ca2+ that enters and is removed from 
the cytosol during each beat. PKA phosphorylation of L-type Cav channels or 
ryanodine receptors increases the amplitude of ICa,L and causes an increased 
amount of Ca2+ released from the sarcoplasmic reticulum (SR) storage during 
each beat, respectively.79-81 Since more Ca2+ accumulates in the cytosol during 
systole in β1-adrenergic receptor stimulation, more Ca2+ must also be removed 
from the cytosol to allow for proper diastolic relaxation. Under basal conditions 
phospholamben inhibits the function of SR Ca2+-ATPase (SERCA), and the main 
function of SERCA is to extrude cytosolic Ca2+ into the SR stores. PKA 
phosphorylation of phospholamben reduces its inhibitory effects on SERCA, and 
increases the rate of Ca2+ reuptake into the SR.82  
 
1.6.2 PKA phosphorylates the N-terminus of Kv7.1 to increase IKs and prevent 
ventricular AP prolongation during sympathetic stimulation 
 During β1-adrenergic receptor stimulation, repolarizing K+ currents must also 
increase to counteract the increases in depolarizing ICa,L in order to prevent AP 
prolongation. Studies show IKs contributes minimally to the ventricular AP at 
basal levels, but IKs amplitude increases during β1-adrenergic receptor 
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stimulation significantly increasing its contribution to repolarization.11 Voltage-
clamp studies show the functional increase of IKv7.1 in response to PKA 
stimulation requires the coexpression of the KCNE1 β-subunit and the A-kinase 
anchoring protein 9 (AKAP9).83 Kv7.1 is phosphorylated by PKA on the N-
terminus at serine-27 (S27-Kv7.1) following β1-adrenergic receptor stimulation, 
causing an increase in outward IKv7.1. AKAP9 binds to the leucine zipper motif of 
the C-terminus of Kv7.1 and recruits PKA, protein phosphatases (PP1 and PP2a), 
and PDE4.84 Therefore, the Kv7.1 macromolecular complex can control the local 
cAMP levels and phosphorylation state of Kv7.1, KCNE1, or AKAP9.83-85 The 
sensitivity of Kv7.1 to PKA stimulation is also influenced by the expression of 
other KCNE β-subunits; whereas, voltage-clamp studies coexpressing KCNE2 
with WT-Kv7.1 permit the functional increase in IKv7.1, but no increase occurs 
when KCNE3 is coexpressed.86 
 
1.6.3 PKA regulation of Kv7.1 and LQT1 
 Risk factors for specific subtypes of LQTS (LQT1, LQT2, or LQT3) are 
elevated during different states of arousal.87, 88 Interestingly, cardiac events are 
typically triggered during exercise when sympathetic tone is elevated in LQT1 
patients. For LQT2 or LQT3 patients, cardiac events occur due to sudden stress 
or during sleep.87 These observations suggest the PKA stimulation for LQT1-
linked mutations should be studied. Also, mutations in the regulatory proteins of 
the Kv7.1 macromolecular complex (KCNE1 and AKAP9) are linked to different 
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subtypes of LQTS (LQT5 and LQT11, respectively), further suggesting the 
importance of IKs-up regulation in response to PKA stimulation.89, 90 
 A recent study suggests that an LQT1 mutation (A341V-Kv7.1) generates 
Kv7.1 channels that are resistant to PKA stimulation (PKA-insensitive), and they 
conclude that this is likely responsible for the unusually severe clinical phenotype 
associated with this mutation.91 Moreover, a separate study shows that patients 
with PKA-insensitive LQT1 missense mutations located in the cytoplasmic loops 
(C-loops) of Kv7.1 also associate with an increased risk for life-threatening 
events.92 These studies continue to demonstrate the important role that PKA 
regulation of Kv7.1 channels has in influencing clinical phenotypes. 
 
1.7 Purpose of dissertation 
1.7.1 Overview of dissertation project 
 Research over the last several decades defines LQT1-linked KCNQ1 
mutations as loss-of-function; whereas, AF-linked KCNQ1 mutations generate a 
gain-of-function phenotype. A clear functional phenotype of a single KCNQ1 
mutation that predisposes a patient to both LQT1 and AF has not been 
determined. Furthermore, the existence of concealed LQTS in patients has not 
been systematically addressed, and understanding why some patients with 
LQT1-linked KCNQ1 mutations do not have prolonged resting QTc intervals 
remains unclear. Therefore, the overall objectives of this dissertation were:  
1) To determine a functional phenotype for KCNQ1 mutations linked to LQT1 
and early-onset AF  
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2) Identify molecular mechanism of latent LQT1 phenotypes 
 
1.7.2 Hypothesis and specific aims 
 The general categorization of LQT1- or AF-linked KCNQ1 mutations as loss- 
or gain-of-function, respectively, is an oversimplification at best. My overall 
hypothesis is that studying the regulation of mutant Kv7.1 channels can link 
functional phenotypes and/or molecular mechanisms with clinical phenotypes. 
Specific Aim 1) To test the hypothesis that KCNQ1 mutations linked to LQT1 
and AF syndromes generate a unique functional phenotype that predisposes 
patients to both arrhythmia syndromes.  
Specific Aim 2) To test the hypothesis that KCNQ1 mutations linked to latent 
LQT1 phenotypes primarily generate relatively normally functioning Kv7.1 
channels that are resistant to PKA stimulation.  
 
1.7.3 Significance of findings 
 The findings of this dissertation will help determine the role of Kv7.1 in atrial 
and ventricular AP repolarization. With these results, I will identify a high-risk 
functional phenotype for early-onset AF in patients with LQT1-linked KCNQ1 
mutations, and distinguish how a relatively benign functional phenotype can 
predispose patients to latent LQT1. Furthermore, this dissertation will help bridge 
the gap between understandings in the clinic and laboratory setting to improve 
mutation-specific risk stratification to better therapeutic interventions of patients 
with KCNQ1 mutations.     
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Figure 1.1 A cartoon of one Kv7.1 α-subunit and KCNE1 β-subunit. Together, 
Kv7.1 α-subunits and KCNE1 β-subunits form a heteromeric channel complex 
that conducts IKs in the heart important for the repolarization phase of the human 
atrial and ventricular AP. 
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Table 1.1 Genes associated with specific subtypes of congenital LQTS 
 
LQTS type Gene Current phenotype Frequency Reference 
LQT1 KCNQ1 IKs,  amplitude ~40% 17 
LQT2 KCNH2 IKr,  amplitude ~40% 93 
LQT3 SCN5A INa,  late current ~10% 94 
LQT4 ANK2 INCX, INKA Rare 95, 96 
LQT5 KCNE1 IKs,  amplitude ~5% 89 
LQT6 KCNE2 IKr,  amplitude ~3% 97 
LQT7 KCNJ2 IK1,  amplitude Rare 98 
LQT8 CACNA1C ICa,  late current Rare 99 
LQT9 CAV3 INa,  late current Rare 100 
LQT10 SCN4B INa,  late current Rare 101 
LQT11 AKAP9 IKs,  amplitude Rare 90 
LQT12 SCNTA1 INa,  late current Rare 102 
LQT13 KCNJ5 IKATP,  amplitude Rare 103 
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Table 1.2 The Schwartz score criteria for diagnosing LQTS patients50 
Schwartz score criteria Points 
ECG findings  
QTc  
≥ 480 ms 3 
460-479 ms (both males and females) 2 
450-459 ms (males) 1 
QTc 4th minute recovery exercise stress test ≥ 480 ms 1 
Torsades de pointes 2 
T-wave alternans 1 
Notched T-wave in 3 leads 1 
Low heart rate for age 0.5 
Clinical history  
Syncope  
Stress induced 2 
Not stress induced 1 
Congenital deafness 0.5 
Family history  
Family member with definite LQTS 1 
Unexplained SCD below age 30 in immediate family member 0.5 
 
• Points are awarded for ECG features only in the absence of an alternative 
cause (medication, hypokalemia, or exercise).  
 
• Probability of LQTS 
o Low = 1 point 
o Intermediate = 1.5 to 3 points 
o High = ≥ 3.5 points 
 
 
 
 
 
 
 
 
 
Copyright © Daniel C. Bartos 2013 
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Chapter 2 
Methods 
 
2.1 Site directed mutagenesis  
For KCNQ1 mutations, the appropriate nucleotide changes were engineered 
in the wild type Kv7.1 (WT-Kv7.1) cDNA cloned in the pcDNA3 plasmid vector 
using the QuickChange II XL Site Directed Mutagenesis Kit (Stratagene; La Jolla, 
CA). All Kv7.1 oligonucleotide primers were generated from Integrated DNA 
Technologies (IDT; Coralville, IA), and the primer sequences are shown in Table 
I. The integrity of all the constructs was verified by DNA sequencing (Advanced 
Genetic Technologies Center, AGTC; University of Kentucky, Lexington, KY). 
Plasmid DNA were replicated and purified using the EndoFree Plasmid Maxi Kit 
(QIAGEN; Valencia, CA).  
 
2.2 Cell culture and transfection 
Human Embryonic Kidney 293 (HEK293) were cultured in Minimum Essential 
Medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS), non-
essential amino acids (NEAA), Penicillin Streptomycin (Pen Strep), and L-
Glutamine (Gibco-Invitrogen; Grand Island, NY) and incubated at 37 °C and 5% 
CO2. HEK293 cells were transiently transfected using SuperFect transfection 
reagent (QIAGEN; Valencia, CA) with WT-Kv7.1 or mutant Kv7.1 (3 µg) and 
KCNEx (3 µg) (KCNE1, KCNE3, KCNE4 or KCNE5 dependent on the 
experiment) plasmid DNA. For coexpression studies, cells were transfected with 
   23 
WT-Kv7.1 (1.5 µg), mutant Kv7.1 (1.5 µg), and KCNEx (3 µg) plasmid DNA. 
Enhanced Green Fluorescent Protein (GFP) cDNA (0.3 µg) subcloned in pKR5 
plasmid vector was also transfected for electrophysiological studies to aid in 
selection. The SuperFect transfection reagent was washed 3 times with OPTI-
MEM reduced serum medium after 3 hours and cells were incubated in normal 
conditions overnight. After 24-30 hours, cells were removed from culture and 
analyzed for electrophysiological studies or lysed for further analysis. For 
perfusion studies or phosphorylation analysis, Kv7.1 (1µg), KCNE1 (1µg), and 
AKAP9 (6µg) plasmid DNA were cotransfected as described above. AKAP9 and 
KCNE1 are required for the phosphorylation and functional response of WT-
Kv7.1 channels to protein kinase A (PKA) activation.  
 
2.3 Electrophysiology 
Functional analyses of whole-cell currents were done using the standard 
whole-cell patch clamp technique on GFP expressing HEK293 cells. The external 
recording solution contained (in mM) 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 
glucose, and 10 HEPES (pH 7.4 with NaOH), and an internal pipette solution 
contained (in mM) 130 KCl, 1 MgCl2, 4 EDTA, 1 EGTA, 5 MgATP, 10 HEPES 
(pH 7.2 with KOH). An Axopatch-200B patch clamp amplifier (Axon Instruments; 
Union City, CA) was used to measure membrane currents and cell capacitance. 
The uncompensated pipette resistances were 1-2 megaohms (MΩ) and series 
resistance was compensated between up to 95%. Only cells with stable 
membrane resistances > 1 gigaohms (GΩ) were studied. The pCLAMP 10 
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software (Axon Instruments; Union City, CA) was used to generate the voltage 
protocols, acquire current signals, and for data analyses. Origin 7.0 (Microcal; 
Northhampton, MA) was used for generating current-voltage (I-V) relations, 
performing Boltzmann curve fitting, and plotting graphs. The I-V data for the 
mean tail currents were fit with the following Boltzmann equation: 
I = (IMIN-IMAX/1+e(V-V½)/k) + IMAX 
where IMIN is the minimally activated current (pA/pF); IMAX is the maximally 
activated current (pA/pF); V½ is the mid-point potential for half maximal 
activation (mV); and k is the slope factor (mV/e-fold change). For all experiments, 
the holding potential was -80 mV, and the dotted line in figures corresponds to 
the zero current baseline. The standard voltage protocol used to record currents 
applied a step-like pulse from -80 mV to 70 mV in 10-mV increments for 5 s, 
immediately followed by a “tail” pulse for 5 s at -50 mV. Voltage-clamp 
experiments were performed at 22-23 °C within 1-2 hours of removing the cells 
from their culture conditions unless noted otherwise.  
For voltage-clamp recordings using an atrial action potential (AP) waveform, a 
waveform was generated from computational simulations of a human atrial AP at 
1 Hz.66, 104 For recording using a ventricular AP waveform, a waveform was 
generated from current clamp recordings of a rabbit ventricular myocyte. The 
appropriate AP waveform was used as the voltage protocol to acquire current at 
1 Hz. The GΩ seal and membrane rupture was obtained at room temperature. 
Cells were then heated to 37 °C using the TC2BIP Temperature Controller (Cell 
MicroControls; Norfolk, VA) before currents were recorded.  
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For perfusion experiments, cells were plated 2 hours prior to recording on 15 
mm round glass coverslips coated with 0.01% rat-tail collagen in 0.25% acetic 
acid. GFP positive cells were recorded with normal extracellular saline as 
previously described. A voltage protocol described in text was run consecutively 
every 15 s until maximal current amplitude reached steady-state for each cell. 
Extracellular bath was replaced via gravity perfusion with fresh extracellular fluid 
containing forskolin (10 µM) to activate adenylate cyclase + 3-isobutyl-1-
methylxanthine (IBMX) (0.2 mM) to inhibit phosphodiesterase activity, collectively 
increasing intracellular levels of cAMP. The voltage protocol was re-run until the 
maximal current amplitude reached its new steady-state amplitude. 
 
2.4 Cell lysis  
Confluent cell cultures were grown in 60 x 10 mm culture dishes and 
transfected with 3 µg Kv7.1 and 3 µg KCNE1 cDNA as described above. Cell 
media was aspirated, and cells were washed 2 times with cell-grade PBS (stored 
at room temperature). 250 µL of 1% NP-40 solubilization buffer was added to 
each dish, and cells were scraped to loosen cells from the dish. NP-40 
solubilization buffer contained: 7.1 mL ddH2O, 1 mL 10% NP-40, 1 mL 100% 
glycerol, 0.5 mL 1M Tris-HCl (pH 7.5), 0.3 mL 5 M NaCl, and 0.1 mL 0.5 M EDTA 
for a total of 10 mL. Protease inhibitor cocktail (Thermo Scientific; Waltham, MA) 
was added at a concentration of 10 µL per 1 mL of NP-40 solubilization buffer. 
The cells were subsequently placed in NP-40 solution in a 1.5 mL centrifuge tube. 
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Prior to Western blotting, cells were placed on ice for immediate use or stored at 
-80 °C. 
 
2.5 Protein quantification  
 Cell lysates were utilized immediately or thawed on ice, and they were 
centrifuged at 13,000 RPM and 4 °C for 15 minutes prior to assaying the protein 
concentration. The protein concentration was measured using the Bio-Rad DC 
Protein Assay (Bio-Rad; Hercules, CA). Protein standards were generated by 
diluting a 2 mg/mL stock of bovine serum albumin, BSA, (Bio-Rad; Hercules, CA) 
into 1% NP-40 solubilization buffer, and a standard absorbance curve was 
generated with an R-value ≥ 0.975 for each experiment. The linear regression of 
the standard absorbance curve was used to calculate the protein concentrations 
of each lysate sample using a SmartSpec Plus Spectrophotometer (Bio-Rad; 
Hercules, CA). Equal amounts of cell lysate protein supernatant and SDS PAGE-
Laemmli (10% DTT) were heated at 95 °C for 5-10 minutes prior to running 
samples on acrylamide gels.  
 
2.6 Biotinylation 
 Confluent cell cultures were grown in 100 x 20 mm culture dishes and 
individually transfected with 6 µg Kv7.1 and 6 µg KCNE1 cDNA as described 
above. After 24 hours, cells were washed three times with PBS on ice. Cell 
surface proteins were isolated using the Pierce Cell Surface Isolation Kit (Pierce; 
Rockford, IL). The surface proteins were treated with Sulfo-NHS-SS-Biotin 
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(Pierce; Rockford, IL) for 30 minutes. After the reaction was quenched, cells were 
washed with refrigerated TBS two times and lysed with NP-40 solubilization 
buffer (1% SDS). Biotinylated proteins were isolated with NeutrAdvin Agarose 
(Pierce; Rockford, IL) and eluted on a heat block at 95 °C for 7-10 minutes. 
Protein concentration was determined similarly to that described above. The cell 
surface proteins were electrophoresed on a 7% acrylamide gel and transferred to 
a nitrocellulose membrane. The nitrocellulose membrane was incubated with 
anti-Kv7.1 (1:3000), anti-Na+/K+-ATPase (1:2000), or anti-calnexin (1:1000). The 
Li-cor Odyssey infrared imaging system was used to image the immunoblots. 
Anti-Kv7.1 was detected using Odyssey Goat anti-Rabbit (1:20,000), and anti-
Na+/K+-ATPase or anti-calnexin were detected using the Odyssey Donkey anti-
Mouse (1:20,000). 
 
2.7 Statistical analysis 
 Data are expressed as the mean ± standard error (SE). For comparisons of 
two groups, an unpaired Student’s t-test with Welch’s correction (to correct for 
unequal variances) was run in order to identify whether the data set differed from 
WT. For recordings involving pharmacological perfusion, a paired Student’s t-test 
with Welch’s correction was run in order to identify whether the data was different 
after perfusion compared to baseline recordings. For comparisons of more than 
two groups, a one-way analysis of variance (ANOVA) with a protected Fisher’s 
LSD post hoc analysis was performed on data sets to determine which 
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experimental group(s) differed from one another. (p<0.05 was considered 
significant) 
 
 
Any variations or additions to these methods are described in the following 
chapters in which they pertain.  
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Table 2.1 Mutagenesis primer sequences for Kv7.1 plasmid DNA 
Mutation 5’-3’ Forward Sequence 5’-3’ Reverse Sequence 
S27A-Kv7.1 CCG GCG GGG CGC CGC GGG CCT 
G 
CAG GCC CGC GGC GCC CCG 
CCG G 
S27D-Kv7.1 CCC GGC GGG GCG ACG CGG 
GCC TGG 
CCA GGC CCG CGT CGC CCC 
GCC GGG 
S140G-Kv7.1 TCT GCC TCA TCT TCG GCG TGC 
TGT CC 
GGT GGA CAG CAC GCC GAA 
GAT GAG G 
V141M-Kv7.1 TGC CTC ATC TTC AGC ATG CTG 
TCC AC 
CGA TGG TGG ACA GCA TGC TGA 
AGA T 
E160K-Kv7.1 GAC TCT CTT CTG GAT GAA GAT 
CGT GCT GGT GGT 
ACC ACC AGC ACG ATC TTC ATC 
CAG AAG AGA GTC 
R231C-Kv7.1 CCA TCA GGG GCA TCT GCT TCC 
TGC AGA TC 
GAT CTG CAG GAA GCA GAT GCC 
CCT GAT GG 
R231H-Kv7.1 CAT CAG GGG CAT CCA CTT CCT 
GCA GA 
GGA TCT GCA GGA AGT GGA TGC 
CCC T  
I235N-Kv7.1 GCA TCC GCT TCC TGC AGA ACC 
TGA GGA TG 
CAT CCT CAG GTT CTG CAG GAA 
GCG GAT GC 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Daniel C. Bartos 2013  
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Chapter 3  
R231C-Kv7.1 is associated with pleiotropic function and expressivity of 
type 1 long QT syndrome and familial atrial fibrillation  
Aspects of this chapter were reported in the Heart Rhythm Journal. 2011 
Jan:8(1):48-55. PMID: 20850564. 
 
3.1 Introduction  
KCNQ1 encodes the pore-forming α-subunit of the voltage-gated K+ channel, 
Kv7.1. In the heart, Kv7.1 coassembles with KCNE1 β-subunits to conduct the 
slowly activating delayed rectifier K+ current, IKs.24, 25 IKs and other K+ currents 
contribute to the repolarization phase of both the atrial and ventricular action 
potentials (AP). Most notably, hundreds of KCNQ1 mutations are associated with 
type 1 long QT syndrome (LQT1) and typically cause a “loss-of-function” in 
heterologous expression systems. Only a few KCNQ1 mutations are linked to 
familial atrial fibrillation, and a gain-of-function phenotype has been implicated to 
be a consequence of these mutations.63, 64  
Several groups identified the missense mutation p.Arg231Cys (R231C-Kv7.1) 
in patients with LQT1, drug-induced long QT syndrome, fetal bradycardia, and 
persistent AF where QTc prolongation was reported after cardioversion.105-110 I 
studied the genotype-phenotype relationships for six unrelated R231C-positive 
families, five of whom have LQT1 and one family contains four genotype positive 
individuals with early-onset AF.111 This chapter discusses the clinical 
characteristics of the six families and provides a functional analysis of R231C-
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Kv7.1. This is the first study to identify a pleiotropic KCNQ1 mutation that 
increases the risk for both LQT1 and early-onset familial AF using genetic and 
functional analyses.  
 
3.2 Clinical evaluation 
3.2.1. Study population and diagnostic criterion 
The R231C-Kv7.1 probands had been referred for genetic testing for 
mutations in LQTS-susceptibility genes. Blood samples were obtained from 
family members who agreed to genetic evaluation and provided written consent. 
Patients underwent clinical evaluation and cardiovascular examination, including 
12-lead ECG and 24-hour Holter recording. Patients with AF appeared to have 
“lone AF” because they have normal thyroid function, no hypertension, or 
structural heart disease as determined by echocardiography. The heart rate 
corrected QTc was considered prolonged if it was ≥ 450 ms for males and ≥ 460 
ms for females using the Bazett formula (QTc for R231C-Kv7.1 subjects are 
given in Table 3.1). The R231C-Kv7.1 subjects with fetal bradycardia were 
previously reported.105  
 
3.2.2 Genetic Analysis 
Patient DNA was extracted from peripheral blood leukocytes using standard 
methods. The probands’ genomic DNA was analyzed for mutations in KCNQ1, 
KCNH2, SCN5A, and KCNE1 (genes linked to LQT1, LQT2, LQT3, and LQT5, 
respectively). The coding regions were amplified using polymerase chain 
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reaction and sequenced with a 3100 BigDye Terminator v3.1 sequencing kit and 
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems; Foster City, CA). In the 
proband of the family associated with familial AF (Family A, subject II:1, Figure 
3.1), we tested for mutations in genes previously linked to AF (KCNE2, KCNE3, 
KCNE5, NPPA, KCNA5, KCNJ2, GJA5, SCN1B, SCN2B, and SCN3B) to 
determine if there were any additional mutations in AF susceptibility genes. We 
also compared 21 single nucleotide polymorphisms (SNPs) that alter AF 
susceptibility among the patients (Families A-F, Figure 3.1).  
 
3.3 Results 
3.3.1 R231C is linked to LQT1, fetal bradycardia, and early-onset AF  
 R231C-Kv7.1 was identified in six probands that presented with a variety of 
clinical phenotypes (Figure 3.1): one with AF (Family A), three neonates with 
fetal bradycardia (Families B, D, and E)105, one with a prolonged QTc interval 
(Family F), and one who is a member of a large LQT1 family previously linked to 
chromosome 11p15 (Family C).112 Although the proband in Family C (I:2) is 
asymptomatic, several other family members are symptomatic for LQTS (not 
shown), including her niece’s baby who was diagnosed with fetal LQTS and 
bradycardia resulting in intrauterine fetal demise at full term (Stillbirth).112 
 In Family A, early-onset AF was diagnosed in the female proband (II:1) at age 
33 years, in her father (I:1) at age 18 years, and in two of her brothers (II:3, II:5) 
at age 30 years and 15 years, respectively. The proband was hospitalized at 33 
years of age for persistent AF. After an electrical cardioversion, she has been 
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treated by sotalol without clinical recurrences until three years after the 
procedure. She was subsequently diagnosed with paroxysmal AF, and the 
sotalol treatment was then replaced by flecainide. She is currently asymptomatic. 
Unlike the other families genotype positive for R231C-Kv7.1, the patients in 
Family A do not manifest either QTc interval prolongation or syncope. However, 
patient II:5 experienced ventricular fibrillation four months after cessation of 
sotalol treatment and died of severe cerebral anoxic damage several days later 
at age 22 years. One patient in Family A (II:4, brother of proband) is thus far 
asymptomatic for AF at age 37 years. None of the patients genotype positive for 
R231C-Kv7.1 with AF have structural heart disease, hypertension, or 
hyperthyroidism consistent with a clinical diagnosis of lone AF. Furthermore, 
genetic testing of the proband (II:1) did not reveal any additional mutations in 
other AF susceptibility genes.  
 No patient genotype positive for R231C-Kv7.1 in Families B, D, E, and F 
present with AF. The proband in Family F (now age 57 years) currently receives 
beta-blocker treatment and underwent defibrillator implantation over three years 
ago following a severe LQTS-triggered cardiac event. Suspecting the possible 
contribution of additional genetic factors to AF development, we genotyped all 
the family members for 21 different SNPs that confer either an in increased risk 
for or are protective of AF susceptibility. We did not find any obvious differences 
between Family A (AF) and Families B-F (LQT1) that might account for their 
disparities in clinical phenotypes, except for possibly rs251253, an intergenic 
SNP located in the region of NKX2-5 gene, which encodes a cardiac-specific 
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homeobox transcription factor. NKX2-5 is associated with regulating cardiac-
specific gene expression, including NPPA. NPPA has been associated with AF in 
recent studies and encodes atrial natriuretic peptide (ANP).66 Indeed, in Family A, 
the son (II:4) was the only R231C-Kv7.1 positive family member who did not 
have AF, but did carry the protective allele. All members carrying R231C-Kv7.1 in 
the LQT1 families (Families B-F) have the protective allele, with the exception of 
patient II:2 of Family C (a women who had not manifested AF at age 33 years). 
This data suggests that R231C-Kv7.1 is primarily linked to LQT1 and fetal 
bradycardia, but also to a lesser extent, early-onset AF.  
 
3.3.2 R231C-Kv7.1 conducts large IKv7.1 and causes a gain-of-function  
 I determined if R231C-Kv7.1 generates a unique functional phenotype that 
predisposes patients to both LQT1 and AF. I chose to study the LQT1 mutation, 
E160K-Kv7.1 as a positive control because like many characterized loss-of-
function LQT1 mutants, E160K-Kv7.1 conducts little or no IKv7.1. I recorded IKv7.1 
from HEK293 cells transfected with KCNE1 and E160K-Kv7.1 or R231C-Kv7.1 
using the whole-cells patch clamp technique (Figure 3.2A). Currents from 
nontransfected cells (HEK) and cells expressing E160K-Kv7.1 or R231C-Kv7.1 
were measured from a holding potential of -80 mV by applying a step-like pulse 
from -80 to 70 mV for 5 s in 10-mV increments followed by a “tail” pulse at -50 
mV for 5 s. At positive potentials, nontransfected cells generated small, 
endogenous outward current and little or no tail current. Similar to nontransfected 
cells, little or no IKv7.1 was measured from cells expressing E160K-Kv7.1. Using 
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the same voltage protocol, cells expressing R231C-Kv7.1 generated large, 
constitutive IKv7.1 that could not be recorded reliably because of apparent 
changes in local [K+] (data not shown). I minimized these effects by shortening 
the duration of the step and tail pulse to 50 ms and 150 ms, respectively, and I 
applied step pulses from -120 to 70 mV in 10-mV increments to determine the 
reversal potential of cells expressing R231C-Kv7.1 (Figure 3.2A). The mean 
peak step current was plotted as a function of voltage to generate the I-V 
relations for cells nontransfected and cells expressing E160K-Kv7.1 or R231C-
Kv7.1 (Figure 3.2B). Importantly, for cells expressing R231C-Kv7.1, inward IKv7.1 
was recorded at negative potentials that appeared to reverse around -80 mV 
suggesting K+ selectivity. Peak tail current was measured upon the immediate 
start of the tail pulse and the mean peak tail currents were plotted as a function 
of the step-pulse potential (Figure 3.2C). Large, outward tail IKv7.1 was measured 
from cells expressing R231C-Kv7.1 at all potentials suggesting these channels 
were always activated at -80 mV (constitutive activation). These data show that, 
although, both E160K-Kv7.1 and R231C-Kv7.1 are linked to LQT1, their effects 
on IKv7.1 are dramatically different from one another.  
 
3.3.3 Coexpression of WT- and R231C-Kv7.1 yields a mixed functional 
phenotype 
 Since both LQT1 and familial AF follow a dominant inheritance pattern, I 
determined the effect that coexpression of WT-Kv7.1 has on E160K-Kv7.1 or 
R231C-Kv7.1. Whole-cell IKv7.1 was measured from cells expressing KCNE1 with 
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WT-Kv7.1, WT- and E160K-Kv7.1, or WT- and R231C-Kv7.1 (Figure 3.3A). IKv7.1 
were recorded using the 5-s voltage protocol in Figure 3.2A. Cells expressing 
WT-Kv7.1 conducted IKv7.1 similar to native IKs. Coexpression of WT- and E160K-
Kv7.1 generated similar IKs–like IKv7.1, but the amplitude was greatly reduced. 
Cells coexpressing WT- and R231C-Kv7.1 showed IKv7.1 with a mixed phenotype 
when compared to cells expressing WT-Kv7.1. At negative potentials, a larger 
outward IKv7.1 in cells coexpressing WT- and R231C-Kv7.1 was observed, but at 
positive potentials, the maximal IKv7.1 amplitude in WT-Kv7.1 expressing cells 
was larger. The mean peak I-V relations measured during the step and tail pulse 
were plotted for cells expressing WT-Kv7.1, WT- and E160K-Kv7.1, or WT- and 
R231C-Kv7.1 (Figure 3.3B and 3.3C, respectively). Mean peak tail IKv7.1 were 
described using a Boltzmann equation to determine IMIN, IMAX, V½, and k for IKv7.1 
activation (Figure 3.3D-F). Cells coexpressing WT- and R231C-Kv7.1 generated 
a larger IMIN than cells expressing WT-Kv7.1 suggesting a constitutive component 
of IKv7.1 persists at all potentials (Figure 3.3D). Cells coexpressing either WT- and 
E160K-Kv7.1 or WT- and R231C-Kv7.1 had a smaller IMAX than cells expressing 
WT-Kv7.1 (Figure 3.3D). Furthermore, cells coexpressing WT- and R231C-Kv7.1 
had a negative V½, whereas compared to cells expressing WT-Kv7.1 or WT- and 
E160K-Kv7.1 (Figure 3.3E). There were no differences in k (Figure 3.3F).  
 These data suggest that cells coexpressing WT- and R231C-Kv7.1 conduct 
smaller IMAX than cells expressing either WT-Kv7.1 or R231C-Kv7.1. To 
determine if this is caused by a reduction in cell surface expression of Kv7.1 
channels, a biotinylation assay was performed. No differences in the relative 
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amount of Kv7.1 expression were observed at the cell surface for cells 
coexpressing WT- and R231C-Kv7.1 (Figure 3.4).   
 I, next, measured IKv7.1 from cells coexpressing KCNE1 with WT-Kv7.1 or WT- 
and R231C-Kv7.1 to determine if constitutive IKv7.1 could be observed using the 
50-ms voltage protocol used to record the large IKv7.1 from cells expressing 
R231C-Kv7.1 (Figure 3.2A). Little or no IKv7.1 was measured for cells expressing 
WT-Kv7.1, but cells coexpressing WT- and R231C-Kv7.1 demonstrated a 
persistent constitutively activated IKv7.1 (Figure 3.5).  
 
3.3.4 Coexpression of WT- and R231C-Kv7.1 reduced IKv7.1 at diastolic potentials 
when recorded using a ventricular AP waveform at 37°C 
 To this point, these data of R231C-Kv7.1 qualitatively resembles the 
functional phenotype of KCNQ1 mutations identified in families with AF.63, 64 To 
determine how R231C-Kv7.1 might contribute to an LQT1 phenotype, I 
measured IKv7.1 using a ventricular AP waveform at 37°C pulsed at 1 Hz from 
nontransfected cells and cells expressing KCNE1 with WT-Kv7.1 or WT- and 
R231C-Kv7.1 (Figure 3.4D). Representative IKv7.1 traces were averaged for 60 
consecutive pulses for each cell (Figure 3.4D).  The small current measured from 
nontransfected cells is a combination of endogenous HEK current and 
uncompensated leak/capacitive currents. Cells expressing WT-Kv7.1 or WT- and 
R231C-Kv7.1 showed large IKv7.1 that peaked during the plateau phase of the AP 
waveform. Cells coexpressing WT- and R231C-Kv7.1 did not alter the mean 
peak IKv7.1 measured during the AP waveform (WT-Kv7.1 = 371 ± 162 pA/pF, n = 
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6; WT- and R231C-Kv7.1 = 335 ± 171 pA/pF, n = 5, p > 0.05). However, cells 
coexpressing WT- and R231C-Kv7.1 had a smaller fraction of IKv7.1 remaining 
during repolarization to diastolic potentials (WT-Kv7.1 = 0.14 ± 0.03; WT- and 
R231C-Kv7.1 = 0 ± 0.03, p < 0.05). We suspect the reduction in IKv7.1 during the 
repolarization phase might increase the risk for LQT1.  
 
3.3.5 Constitutive IKv7.1 of R231C-Kv7.1 is not dependent of KCNE1 expression 
 To determine if the constitutive IKv7.1 was dependent on expression of KCNE1 
subunits, I measured IKv7.1 from nontransfected cells and cells expressing WT-
Kv7.1 or R231C-Kv7.1 using the 5-s voltage protocol described in Figure 3.2 
(Figure 3.6A). The mean peak step and tail I-V relations were plotted as a 
function of the step pulse potential (Figure 3.6B and 3.6C, respectively). Cells 
expressing WT-Kv7.1 generated small, outward IKv7.1 at positive potentials that 
demonstrated voltage dependence of activation; whereas, cells expressing 
R231C-Kv7.1 generated a small, outward tail IKv7.1 at all potentials tested. These 
data suggest that constitutive activation of R231C-Kv7.1 does not depend on 
KCNE1 expression.  
 
3.4 Discussion 
 This is the first study to link a known LQT1 mutation, R231C-Kv7.1, to familial 
AF and show that an LQT1 mutation can be associated with a gain-of-function 
phenotype similar to other KCNQ1-mediated AF mutations.63-66 Sequencing 
additional AF-associated genes did not identify additional mutations in the 
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probands genotype positive for R231C-Kv7.1. Additionally, twenty-four subjects 
from the six families genotype positive for R231C-Kv7.1 were genotyped for 21 
AF-susceptibility altering SNPs. The only correlation observed was with a 
protective allele in the NKX2-5 gene in the LQT1 families, which encodes the 
cardiac homeobox Nkx2-5 transcription factor.113 The majority of patients 
genotype positive for R231C-Kv7.1 who did not have AF diagnosed were positive 
for this SNP suggesting this allele is protective of AF. The only exceptions were a 
male patient (I:1 of Family A) who was diagnosed with AF and carried the 
protective allele, and a female patient (II:2 of Family C) who did not have AF and 
did not have the protective allele. This reiterates the concept that genetic 
screening for susceptibility alleles is not perfect at predicting clinical outcomes 
and patient specific differences may contribute to unexplained clinical 
observations.  
 In heterologous expression systems, cells coexpressing WT- and R231C-
Kv7.1 generates a mixed functional phenotype: a persistent IKv7.1 was present at 
negative potentials (suggesting constitutive activation similar to other KCNQ1 
mutations linked to familial AF)63, 64, and a smaller IMAX alike KCNQ1 mutations 
linked to LQT1.110 To determine the functional consequence of R231C-Kv7.1 on 
the cardiac AP duration, we generated computational simulations of a human 
atrial or ventricular AP by altering the IKs component to represent our biophysical 
findings. We reduced the total number of functional IKs component by 50% and 
incorporated a minimum open probability of the IKs component to 6.25% for 
simulations of a human ventricular and atrial AP model (Figure 3.7A and 3.7B, 
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respectively).66, 104, 114 The minimum open probability was set to 6.25% under the 
assumption that due to random coassembly of Kv7.1 α-subunits, 6.25% (1/16) of 
the population of IKs channels will be homomeric mutant channels. At 1 Hz cycle 
frequency, the atrial AP duration was reduced by over 50% (Figure 3.7A), and 
the ventricular AP duration was reduced by only about 1% (Figure 3.7B). The 
shortening of atrial AP duration and refractoriness has been known to serve as a 
substrate to electrical reentry, which can initiate AF.55 The modeling suggests 
R231C-Kv7.1 biophysical properties most likely affect the atrial AP duration in 
basal conditions because the atrial AP depolarizes to less positive potentials and 
atrial myocytes have been predicted to have a larger IKs density than ventricular 
myocytes.115 Furthermore, small increases in the open probability of IKs channels 
preferentially increased the IKs density in atrial myocytes and this may explain the 
lack of QTc interval shortening in AF patients positive for gain-of-function KCNQ1 
mutations.63, 65, 66 On the other hand, the lack of ventricular AP prolongation due 
to a 50% reduction in IKs density is not a surprise because studies have shown 
that use of IKs blocker (chromanol 293B) in isolated ventricular myocytes does 
not prolong the ventricular AP duration and IKs density is small in basal 
conditions.116-118 Since LQT1-associated events are typically triggered during 
situations involving elevation of sympathetic tone such as β-adrenergic activation 
during exercise, reductions in IKs may be more impactful during these 
circumstances.119 
 This was the first study linking a known LQT1 mutation to familial AF. R231C-
Kv7.1 generates a bipartite functional phenotype when coexpressed with WT-
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Kv7.1 causing an increase in constitutive IKv7.1 at negative potentials and a 
reduction in IMAX. I conclude the mixed functional phenotype of R231C-Kv7.1 can 
predispose patients to LQT1, familial AF, or both.   
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Figure 3.1 R231C-Kv7.1 genotype positive families. Shown are pedigrees for 
six families genotype positive for R231C-Kv7.1 (A., B., C., D., E., and F.). Males 
and females are represented as squares and circles, respectively. The different 
generations are denoted using Roman numerals, and each individual in a 
generation is numbered. The genotype/phenotypes are defined in the key. 
Prolonged QTc interval is defined as ≥ 450 ms for males or ≥ 460 ms for females.  
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Figure 3.2 Cells expressing R231C-Kv7.1 conduct large, constitutive IKv7.1. A. 
Representative families of whole-cell current recorded from nontransfected cells 
(HEK, black squares, n = 10), cells transfected with KCNE1 and E160K-Kv7.1 
plasmid DNA (E160K, blue open circles, n = 8), or cells transfected with KCNE1 
and R231C-Kv7.1 plasmid DNA (R231C, red triangles, n = 20). The voltage 
protocols used are shown above the current traces. Mean peak step (B) and tail 
(C) IKv7.1 are plotted as a function of the step pulse potential.  
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Figure 3.3 Cells coexpressing WT- and R231C-Kv7.1 yield a bipartite 
functional phenotype. A. Representative families of IKv7.1 measured from cells 
expressing KCNE1 and WT-Kv7.1 (WT, black squares, n = 31), WT- and E160K-
Kv7.1 (WT & E160K, blue open circles, n = 13), or WT- and R231C-Kv7.1 (WT & 
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R231C, red triangles, n = 22). Mean peak step (B) and tail (C) IKv7.1 are plotted as 
a function of the step pulse potential for cells expressing WT-Kv7.1, WT- and 
E160K-Kv7.1, or WT- and R231C-Kv7.1. Mean peak tail IKv7.1 were measured at 
the initiation of the tail pulse and were described using a Boltzmann equation 
(gray line, Figure 3.2C). The Boltzmann equation calculated the mean IMIN and 
IMAX (D), V½ (E), and slope factor, k (F).  (* p < 0.05 vs. cells expressing WT-
Kv7.1) 
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Figure 3.4 Cell surface expression of R231C-Kv7.1. A. Shown are 
representative immunoblots of cell surface proteins from cells expressing WT-, 
E160K-, R231C-, or WT- and R231C-Kv7.1. Also shown is a representative 
immunoblot of the Whole Cell Lysate (WCL) from non-transfected cells. The top 
blots show immunolabeling with anti-Kv7.1, the middle blots show 
immunolabeling with anti-Na+/K+-ATPase (used as a positive control of cell 
surface expression), and the bottom blots show immunolabeling with calnexin 
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(used as a negative control of an intracellular protein). B. The graph shows the 
mean ratio of anti-Kv7.1 and anti-Na+/K+-ATPase densitometries. (n = 4) 
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Figure 3.5 Cells coexpressing WT- and R231C-Kv7.1 generate constitutively 
activated IKv7.1 at negative potentials and reduce IKv7.1 during ventricular AP 
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repolarization. A. Representative families of whole-cell IKv7.1 recorded from cells 
expressing KCNE1 and WT-Kv7.1 (WT, black squares, n = 11) or WT- and 
R231C-Kv7.1 plasmid DNA (R231C, red triangles, n = 13). IKv7.1 was measured 
by applying step-like pulses from -120 to -10 mV at 10-mV increments for 50 ms, 
immediately followed by a tail pulse to -50 mV for 150 ms. The corresponding 
mean peak step (B) and tail (C) IKv7.1 are plotted as a function of the step pulse 
potential. D. The ventricular AP waveform used to record current at 37°C is 
shown. The corresponding current traces were averaged after 60 consecutive 
pulses (at 1 Hz frequency) from nontransfected cells (HEK, gray line, n = 4), and 
cells transfected with KCNE1 and WT-Kv7.1 plasmid DNA (WT, black line, n = 5) 
or WT- and R231C-Kv7.1 plasmid DNA (WT & R231C, red line, n = 5).  
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Figure 3.6 Cells expressing R231C-Kv7.1 conduct constitutive IKv7.1 without 
expressing KCNE1. A. Representative families of whole-cell IKv7.1 recorded from 
nontransfected cells (HEK, open diamonds), cells transfected with WT-Kv7.1 
plasmid DNA (WT, black squares) or cells transfected with R231C-Kv7.1 plasmid 
DNA (R231C, open red triangles) are shown. The voltage protocol used to 
measure the IKv7.1 was similar to the 5-s voltage protocol used in Figure 3.2. The 
mean peak step (B) and tail (C) IKv7.1 are plotted as a function of the step voltage 
for nontransfected cells, cells expressing WT-Kv7.1 or cells expressing R231C-
Kv7.1.	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Figure 3.7 Computational simulations of human atrial and ventricular AP. 
Computational model of a human atrial (A) or ventricular (B) AP waveform 
pulsed at 1 Hz and the corresponding IKs density and channel open probability is 
displayed. Blue traces represent control IKs, and red traces represent simulations 
in which the IKs component was altered to incorporate a 50% reduction in the 
number of functional channels and a minimum open probability of 6.25%. (The 
computational simulations were performed in collaboration with Dr. Don E. 
Burgess) 
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Table 3.1 QTc values for patients genotype positive for R231C-Kv7.1. QTc 
interval was calculated using Bazett’s formula46: 
QTc = QT/√RR 
LQT1 was defined as having a QTc interval ≥ 450 ms for males and ≥ 460 ms for 
females.  
Family:subject QTc (ms) AF LQT1 
A I:1 382 Yes No 
A II:1 417 Yes No 
A II:3 368 Yes No 
A II:4 398 No No 
A II:5 407 Yes No 
B I:2 442 No No 
B II:1 425 No No 
B II:2 424 No No 
B II:3 503 No Yes 
C II:2 486 No Yes 
D II:1 432 No No 
D III:1 527 No Yes 
E II:1 460 No Yes 
E II:2 480 No Yes 
E III:1 545 No Yes 
E III:2 476 No Yes 
F I:2 471 No Yes 
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Chapter 4 
R231H-Kv7.1 provides direct evidence of a KCNQ1 mutation causing early-
onset atrial fibrillation 
Aspects of these data presented in this chapter were published in the Journal of 
Cardiovascular Electrophysiology. Epub 2012 Dec 11. PMID: 23350853. 
 
4.1 Introduction 
 AF is the most common sustained cardiac arrhythmia syndrome, and patients 
with AF may experience palpitations, syncope, congestive heart failure, and an 
increased risk of stroke.120-124 Familial reports of AF have been studied for over 
70 years, but understanding the direct genetic linkage has been difficult to 
interpret for clinician scientists.62 Although rare, KCNQ1 mutations have recently 
been increasingly associated to familial AF in multigenerational families.63-66, 111 
All of these mutations have only been linked to familial AF in one patient or one 
family each, and several mutations have been identified in additional families 
associated with LQT1 or indicated as SNPs in the general population.111, 125 
Identifying familial AF in multiple unrelated families would represent a significant 
finding in understanding the genetic and molecular role of KCNQ1 to familial AF.  
 In the previous chapter, we described an LQT1 mutation (p.Arg231Cys or 
R231C-Kv7.1) that caused a gain-of-function phenotype by producing 
constitutive IKv7.1 at negative potentials; however, it also caused a loss-of-function 
by decreasing the IMAX by > 50% when co-expressed with wild-type (WT-Kv7.1). 
Clinical phenotypes from six different families suggested that R231C-Kv7.1 
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conferred a higher risk for LQT1, because five of the six genotype positive 
families have LQT1 without AF and only one family has familial early-onset AF 
without LQT1. In this chapter, we discuss the identification of a similar missense 
mutation, p.Arg231His (R231H-Kv7.1), in five unrelated families with a history of 
familial early-onset AF.126 Previous reports linked R231H-Kv7.1 to LQT1 and 
more recently to early-onset AF.70, 127 The purpose of this chapter is to identify a 
potential mechanism for the high incidence of early-onset AF in patients 
genotype positive for R231H-Kv7.1 using functional and computational analysis. 
 
4.2 Results 
4.2.1 Genetic screening 
 We identified five unrelated probands who are genotype positive for the LQT1 
mutation R231H-Kv7.1 (Figure 4.1). The proband in Figure 4.1A was reported 
previously.70 The Institutional Ethics Committees approved the respective 
protocols for research-based genetic analysis for patients with LQTS and the 
patients provided informed consent before either research testing or clinical 
testing with one of the commercially available LQTS genetic tests. Genomic DNA 
was performed using standard methods. The DNA of probands from families A, C, 
and E were negative for additional mutations when screened in other autosomal 
dominant AF-related genes (KCNH2, SCN5A, KCNJ2, KCNE1, KCNE2). The 
proband in families B and D were negative for mutations in SCN5A.  
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4.2.2 R231H-Kv7.1 is prevalent among families with a history of familial early-
onset atrial fibrillation 
 R231H-Kv7.1 was initially reported in a single patient with LQT1,127 and 
subsequently in a one-year-old female patient suspected of having LQT1.70 
Although, the patient data for these individuals are limited, the latter patient has 
early-onset AF and only a borderline QTc interval of 480 ms (Figure 4.1A). 
Unfortunately, the current status of this patient and other family members are not 
available.  
 We now report the clinical phenotypes for four additional families genotype 
positive for R231H-Kv7.1. The probands were referred for genetic testing 
because they are symptomatic for atrial and ventricular arrhythmias (Figure 4.1B-
E), including sudden cardiac arrest while sleeping (Family B), fetal bradycardia 
(Family C), or familial AF (Family D and E).  
 In family B, the proband is a 20 year-old male (II:1) who presented with 
ventricular fibrillation while sleeping. He was successfully resuscitated, but was 
subsequently diagnosed with early-onset AF. The patient received two 
unsuccessful direct current cardioversions (DCCVs) and underwent one 
unsuccessful pulmonary vein isolation. Sinus rhythm was maintained for a short 
time with amiodarone, but he is currently in persistent AF and receiving β-blocker 
therapy. The patient’s mother (I:2) is positive for R231H-Kv7.1, was diagnosed 
with early-onset AF at 6 years of age, and has received two unsuccessful DCCVs. 
Following the index patient’s cardiac arrest, his sister (II:2, age 24) and brother 
(III:3, age 16), were also found to be genotype positive for R231H-Kv7.1 and in 
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AF. The brother (but not the sister) was successfully treated with DCCV. All 
members of family B that are positive for R231H-Kv7.1 have AF and normal QTc 
intervals. 
 The proband in family C (III:1) was born by cesarean section at gestational 
age 32 weeks prompted by fetal bradycardia. Since then, he has had multiple 
ECGs and no abnormalities have been observed. The proband’s mother (II:2), 
maternal grandmother (I:2), and brother (III:2) all tested positive for R231H-Kv7.1, 
and all have normal QTc intervals. Both the mother and maternal grandmother 
were diagnosed with early-onset AF at 16 years of age. Currently, the brother is 
asymptomatic.  
 In family D, early-onset AF was diagnosed in the female proband (III:1) at age 
14, and in her mother (II:2), maternal aunt (II:3), and maternal uncle (II:4). The 
proband underwent successful DCCV for one year but the patient is now in AF. 
Holter monitor showed multifocal ventricular ectopy with bigeminy, trigeminy, and 
couplets, and although her resting QTc interval was normal, epinephrine testing 
unmasked QTc interval prolongation using the Shimizu protocol.128 The 
proband’s sister (III:2) is also genotype positive for R231H-Kv7.1. Holter 
monitoring of the sister also showed frequent ventricular ectopy and a normal 
QTc interval, but she is thus far asymptomatic for AF. Although not genetically 
tested, the patient’s mother and maternal aunt both died suddenly while sleeping 
at the ages of 60 and 55 years, respectively.  
 The final proband of family E (I:2) first developed paroxysmal early-onset AF 
at age 32 and has experienced 10 episodes of AF over the last 14 years with 
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each event requiring DCCV to restore normal sinus rhythm. On several 
occasions, ECG or echocardiogram testing suggested that this patient has a 
normal QTc interval, heart structure, and heart function. The proband was 
adopted and has no documented family history of AF from previous generations. 
Two out of three children were found genotype positive for R231H-Kv7.1, and her 
youngest daughter was negative. Her son (II:1) developed paroxysmal early-
onset AF at age 13 with at least 2 episodes, experienced significant bradycardia, 
and has a prolonged QTc interval. The eldest daughter (II:2) developed early-
onset AF at age 16 with a normal QTc interval. Both AF-bearing children required 
DCCV to regain normal sinus rhythm. Overall, the mean QTc interval value for 
the fourteen patients genotype positive for R231H-Kv7.1 among the five 
unrelated families is in the normal range (mean 444 ± 20 (SD) ms). 
 
4.2.3 Cells coexpressing WT- and R231H-Kv7.1 increase IKv7.1 at negative 
membrane potentials, but do not decrease maximally activated IKv7.1 
 The clinical data are the first to link a single KCNQ1 mutation to familial early-
onset AF in multiple unrelated families. The high penetrance of AF within 
individual families suggests this mutation might generate a unique functional 
phenotype that conveys a high risk for early-onset AF. To test this, I coexpressed 
KCNE1 with WT-Kv7.1, R231H-Kv7.1, or WT- and R231H-Kv7.1 in HEK293 cells 
and recorded macroscopic IKv7.1 by applying the 5-s voltage protocol described in 
Chapter 3 (Figure 4.2). The peak IKv7.1 recorded during the step pulse or at the 
initiation of the tail pulse was plotted as a function of the step pulse potential to 
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generate step and tail I-V relations (Figure 4.2B and 4.2C, respectively). The 
peak tail I-V relations were described with a Boltzmann equation for cells 
expressing WT-Kv7.1 or WT- and R231H-Kv7.1 (Figure 4.2C). Cells expressing 
R231H-Kv7.1 conducted IKv7.1 that was activated at all potentials tested and 
showed little or no voltage dependence of activation. An intermediate phenotype 
was observed for cells coexpressing WT- and R231H-Kv7.1; whereas, they 
generated a larger IMIN than cells expressing WT-Kv7.1 suggesting a constitutive 
component of IKv7.1 was present at negative potentials (Figure 4.2D). Also, 
compared to cells expressing WT-Kv7.1, cells coexpressing WT- and R231H-
Kv7.1 did not alter IMAX (Figure 4.2E), had a more negative V½ (Figure 4.2F), and 
a larger k (Figure 4.2G).  
 To more clearly determine whether cells coexpressing WT- and R231H-Kv7.1 
have constitutively activated IKv7.1 at a -80 mV, I applied 50 ms step pulses from -
120 to -50 mV in 10-mV increments followed by a 150 ms tail pulse to -50 mV 
(Figure 4.3A). The mean peak step or tail I-V relations were generated by plotting 
the peak IKv7.1 measured at the start of each pulse as a function of the step pulse 
potential (Figure 4.3B and 4.3C, respectively). Almost no step or tail IKv7.1 was 
observed for cells expressing WT-Kv7.1, but cells coexpressing WT- and R231H-
Kv7.1 generated inward and outward step current that reversed around -80 mV. 
Additionally, cells coexpressing WT- and R231H-Kv7.1 also generated outward 
tail IKv7.1 at all potentials tested. These data clearly demonstrate that cells co-
expressing WT and R231H-Kv7.1 have constitutively activated IKv7.1 at -80 mV, 
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but cells expressing WT-Kv7.1 do not. Biotinylation experiments showed the cell 
surface expression of WT-Kv7.1 and R231H-Kv7.1 was not different (Figure 4.4).  
 
4.2.4 Cells coexpressing WT- and R231H-Kv7.1 increase IKv7.1 when recorded 
using an atrial AP waveform 
 I determined if cells coexpressing WT- and R231H-Kv7.1 increased IKv7.1 
recorded using a human atrial AP waveform. To do this, I voltage-clamped cells 
expressing KCNE1 with WT-Kv7.1 or WT- and R231H-Kv7.1 at 37 °C (to mimic 
physiological temperature) and pulsed the cells with an atrial AP waveform at a 
frequency of 1 Hz (Figure 4.5A). The atrial AP waveform was generated from 
computational simulations of a human atrial AP pulsed at 1 Hz.66, 104 I averaged 
the IKv7.1 recorded from 50 consecutive pulses. Pulsing cells expressing WT-
Kv7.1 activated a small amount of IKv7.1, but cells coexpressing WT- and R231H-
Kv7.1 showed a large outward IKv7.1 (Figure 4.5B).   
 
4.2.5 R231H-Kv7.1 preferentially shortens the atrial AP duration in computational 
simulations 
 We performed simulations of a computational model of a human atrial AP to 
determine the effect R231H-Kv7.1 has on atrial AP duration over a wide range of 
cycle lengths.66, 107 To mimic the biophysical properties of R231H-Kv7.1, we 
altered the IKs component to maintain an open probability of 6.25%, representing 
constitutive activation at negative potentials. This is the fraction of IKs that is 
predicted to be constitutively active based on random coassembly of WT- and 
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R231H-Kv7.1 α-subunits, and it coincides with the experimental data. This is 
similar to the simulations discussed in the previous chapter, except we do not 
reduce the number of IKs channels; therefore, we are not reducing the maximal 
IKs. We did, however, perform separate simulations that completely lacked the IKs 
component to compare the effects a loss-of-function KCNQ1 mutation has on the 
atrial AP duration. Comparable to before, the small increase in open probability 
of the IKs component to 6.25% at rest will cause a range of shortening ~ 40 - 60% 
of the atrial AP duration at all cycle lengths tested (Figure 4.6B). On the other 
hand, the simulation that completely lacked IKs displayed only a minor (< 10%) 
prolongation in the atrial AP duration.  
 
4.2.6 Cells coexpressing KCNE3 and R231H-Kv7.1 decrease voltage-dependent 
gating of activation 
 In both the human atria and ventricles, Kv7.1 has been suggested to interact 
with other KCNE β-subunits (KCNE2-5) that can alter the biophysical properties 
of IKs.27-30, 129, 130 KCNE2, KCNE4, and KCNE5 are all inhibitory, but KCNE3 
increases IKv7.1 similar to KCNE1 and stabilizes the Kv7.1 voltage-sensor in a 
semi-conductive state to generate a constitutive IKv7.1, which can be activated to 
a fully conductive state upon membrane depolarization.29, 131, 132 Since, WT-Kv7.1 
is positively regulated by KCNE3, I expressed KCNE3 with WT-Kv7.1 or R231H-
Kv7.1 to determine how KCNE3 regulates the function of R231H-Kv7.1. IKv7.1 
were measured by applying step pulses from -80 to 70 mV in 10-mV increments 
for 2 s, followed by a tail pulse for 2 s at -50 mV for cells expressing KCNE3 with 
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WT-Kv7.1 or R231H-Kv7.1 (Figure 4.7A). The mean peak IKv7.1 recorded during 
the step pulse (Figure 4.7B) or at the initiation of the tail pulse (Figure 4.7C) was 
plotted as a function of the step pulse potential to generate I-V relations. Similar 
to previous recordings, the mean peak tail I-V relations were described with a 
Boltzmann equation to determine IMIN (Figure 4.7D), IMAX (Figure 4.7E), V½ 
(Figure 4.7F), and k (Figure 4.7G). Cells expressing R231H-Kv7.1 conducted a 
minimally activated IKv7.1 comparable to cells expressing WT-Kv7.1, but the IMAX 
was much smaller (Figure 4.7D and 4.7E, respectively). Coexpressing KCNE3 
with R231H-Kv7.1 yielded a seemingly opposite result as to what was seen in 
cells expressing KCNE1 (Figure 4.2). Cells expressing KCNE1 with R231H-
Kv7.1 conducted primarily maximally activated IKv7.1 (IMAX); whereas expressing 
KCNE3 with R231H-Kv7.1 elicited primarily minimally activated IKv7.1 (IMIN). In 
both instances, the voltage dependence of activation is almost completely 
disrupted. I also tested the inhibitory effects of KCNE4 and KCNE5, but the 
corresponding currents were small and I did not detect any differences between 
IKv7.1 measured from cells expressing WT-Kv7.1 or R231H-Kv7.1 (data not 
shown). 
 
4.2.7 Parallel functional analysis of AF-linked KCNQ1 mutations that elicit 
constitutive activation of Kv7.1 
 Thus far, eight KCNQ1 mutations are linked to AF, but only four have been 
shown to increase the constitutive activation of IKs.63-66, 71, 111, 126, 133 As with 
R231C-Kv7.1 and R231H-Kv7.1, each mutation equates with a different clinical 
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phenotype among genotype positive families. Therefore, I sought to determine if 
the KCNQ1 mutations that cause constitutive activation of Kv7.1 (S140G-Kv7.1, 
V141M-Kv7.1, R231C-Kv7.1, and R231H-Kv7.1) had distinct functional 
phenotypes when compared side-by-side. I coexpressed KCNE1 with WT-Kv7.1, 
WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1, or WT- 
and R231H-Kv7.1 and recorded IKv7.1 by applying the 5-s voltage protocol 
previously described in chapter 3 (Figure 4.8A). The mean peak step (Figure 
4.8B) and tail (Figure 4.8C) I-V relations were plotted as a function of the step 
pulse potential. The peak tail I-V relations were described with a Boltzmann 
equation for cells expressing WT-Kv7.1, WT- and S140G-Kv7.1, WT- and 
V141M-Kv7.1, WT- and R231C-Kv7.1 or WT- and R231H-Kv7.1 (Figure 4.8C). 
All cells coexpressing WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and 
R231C-Kv7.1, or WT- and R231H-Kv7.1 conducted a IMIN that was larger than 
cells coexpressing WT-Kv7.1, suggesting they all generate a similar amplitude of 
constitutively active IKv7.1 at negative potentials (Figure 4.8D). Interestingly, cells 
coexpressing WT- and S140G-Kv7.1, WT- and V141-Kv7.1, or WT- and R231C-
Kv7.1 had an IMAX that was less than WT-Kv7.1 expressing cells, but cells 
coexpressing WT- and R231H-Kv7.1 did not (Figure 4.8E). All cohorts of cells 
caused a negative shift in the V½ compared to cells expressing WT-Kv7.1 
(Figure 4.8F). When compared to each other, cells coexpressing WT- and 
R231C-Kv7.1 had a smaller IMAX than cells expressing WT- and R231H-Kv7.1. 
These data were consistent with our previous reports that suggested that R231C-
Kv7.1 reduces IMAX, but R231H-Kv7.1, does not.111, 126  
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4.3 Discussion 
 In this chapter we report five unrelated families genotype positive for R231H-
Kv7.1, and all five families have a history of familial early-onset AF. This is the 
first study to identify a single KCNQ1 variant in separate families with familial AF. 
In vitro analyses demonstrated that R231H-Kv7.1 primarily caused a gain-of-
function phenotype by causing constitutively active IKs at negative potentials. 
Unlike R231C-Kv7.1, R231H-Kv7.1 did not reduce IMAX. 
 IKv7.1 recorded from cells coexpressing WT- and R231H-Kv7.1 were much 
larger than cells expressing WT-Kv7.1 using an atrial AP waveform suggesting 
that heteromeric IKs channels will lead to a shortening of the atrial AP. Similarly to 
the previous chapter, we showed using atrial AP simulations that increasing the 
open probability of IKs channels by 6.25% will cause ~ 50% shortening of the 
atrial AP duration. This is expected to decrease the distance an electrical impulse 
travels in one refractory period (cardiac wavelength). If the cardiac wavelength 
becomes shorter than the path-length of the electrical impulse, then multiple 
reentry circuits can develop to induce fibrillation.55, 69, 134 The computational 
modeling of an atrial AP across a range of cycle lengths suggests that the 
shortening of the atrial AP duration is greater as the cycle length is increased 
(Figure 4.6B). Interestingly, analogous functional effects of increasing IKs at 
negative potentials do not cause abnormal shortening of the ventricular AP 
duration.111 
 One of the reasons R231H-Kv7.1 causes constitutively activated IKv7.1 may be 
due to its positioning. R231H-Kv7.1 disrupts a highly conserved arginine residue 
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in the Kv7.1 S4 voltage sensor transmembrane segment. Like other voltage 
gated K+ channels, the S4 of Kv7.1 is responsible for sensing membrane 
potential changes, and depolarization drives S4 towards the extracellular side of 
the plasma membrane to stabilize the maximally activated state.8 Our data 
suggests that R231H-Kv7.1 stabilized the maximally activated state when 
expressed with KCNE1 (Figure 4.2C). In contrast to KCNE1, KCNE3 modulates 
WT-Kv7.1 to favor a partially conducting “closed” state rather than a 
nonconducting closed state at negative membrane potentials, and upon 
membrane depolarization Kv7.1 further activates to a new more conductive state 
(Figure 4.7C).29, 132 Surprisingly, cells expressing KCNE3 and R231H-Kv7.1 
stabilized the partially conducting closed state, but not the maximally activated 
state (Figure 4.7C). This suggests that R231H-Kv7.1 causes S4 immobilization in 
a KCNE1 or KCNE3 dependent manner. Coexpression of R231H-Kv7.1 with 
KCNE1 immobilizes the S4 to the maximally activated position, and coexpression 
of KCNE3 immobilizes S4 into its minimally activated position. 
 In direct comparison to other AF-linked KCNQ1 mutations to WT-Kv7.1, I 
found R231H-Kv7.1 is the only mutation that does not reduce IMAX when 
coexpressed with WT-Kv7.1 (Figure 4.8C). This is not surprising because many 
patients genotype positive for S140G-Kv7.1 or R231C-Kv7.1 have prolonged 
QTc interval or are diagnosed with LQT1.63, 111 On the other hand, the patient 
genotype positive for V141M-Kv7.1 did not have QT interval prolongation, but 
coexpression of WT- and V141M-Kv7.1 did reduce IMAX.64 The discrepancy in 
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these results could be due to the fact that V141M-Kv7.1 was discovered in only 
one patient as a de novo mutation.  
 In summary, R231H-Kv7.1 is different than R231C-Kv7.1 and other AF-linked 
KCNQ1 mutations, and R231H-Kv7.1 causes a high-risk functional phenotype for 
early-onset AF. The prevalence of the R231H-Kv7.1 mutation as a cause of 
early-onset AF in large cohorts remains unknown (and likely represents a small 
number). Additionally, some AF-susceptibility genes were not screened in these 
patients. However, the presence of this rare KCNQ1 variant in multiple kindreds 
with appropriate segregation and AF, the biophysical findings observed, and the 
known association of KCNQ1 with familial AF strongly support a contribution of 
R231H-Kv7.1 to AF vulnerability. R231H-Kv7.1 provides a strong molecular link 
to the manifestation of early-onset AF in unrelated families. Our studies indicate 
that R231H-Kv7.1 likely increases the amount of IKs during the atrial AP to 
dramatically shorten its duration. I conclude genetic variants that shorten atrial 
refractoriness will present a high risk for interfamilial early-onset AF.  
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Figure 4.1 R231H-Kv7.1 confers a high risk for early-onset AF. Pedigrees of 
five non-related families (A., B., C., D., and E.) genotype positive for R231H-
Kv7.1 are identified. Individual males or females are represented as squares or 
circles, respectively; each generation is denoted by a Roman numeral; and the 
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patients’ clinical phenotypes/genotypes are defined in the key. Prolonged QTc 
interval is defined as ≥ 450 ms for males or ≥ 460 ms for females.  
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Figure 4.2 Cells coexpressing WT- and R231H-Kv7.1 do not reduce IMAX. A. 
Representative families of IKv7.1 measured from cells expressing KCNE1 and WT-
Kv7.1 (WT, black squares, n = 18), R231H-Kv7.1 (R231H, blue filled triangles, n 
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= 11), or WT- and R231H-Kv7.1 (WT & R231H, blue open triangles, n = 15). 
Mean peak step (B) and tail (C) IKv7.1 are plotted as a function of the step pulse 
potential for cells expressing WT-Kv7.1, R231H-Kv7.1, or WT- and R231H-Kv7.1. 
Peak tail IKv7.1 for were measured at the initiation of the tail pulse and the tail I-V 
relations of cells expressing WT-Kv7.1 or WT- and R231H-Kv7.1 were described 
using a Boltzmann equation (gray line, Figure 4.2C). The Boltzmann equation 
calculated the mean IMIN (D), IMAX (E), V½ (F), and slope factor, k (G).  (* p < 0.05 
vs. cells expressing WT-Kv7.1) 
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Figure 4.3 Cells coexpressing WT- and R231H-Kv7.1 generate constitutive 
IKv7.1 similar to R231C-Kv7.1. A. Representative families of whole-cell IKv7.1 
recorded from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, n = 
15) or WT- and R231H-Kv7.1 plasmid DNA (WT & R231H, blue open triangles, n 
= 11). IKv7.1 was measured by applying step-like pulses from -120 to -50 mV at 
10-mV increments for 50 ms, immediately followed by a tail pulse to -50 mV for 
150 ms. The corresponding mean peak step (B) and tail (C) IKv7.1 are plotted as a 
function of the step pulse potential. 
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Figure 4.4 R231H-Kv7.1 does not alter cell surface expression. A. Shown are 
representative immunoblots of cell surface proteins isolated via biotinylation from 
cells expressing WT-Kv7.1 or R231H-Kv7.1. Also shown is a representative 
immunoblot of the Whole Cell Lysate (WCL) from non-transfected HEK293 cells. 
The top blots show immunolabeling with anti-Kv7.1, the middle blots show 
immunolabeling with anti-Na+/K+-ATPase (used as a positive control of cell 
surface expression), and the bottom blots show immunolabeling with calnexin 
(used as a negative control of an intracellular protein). B. The graph shows the 
mean ratio of anti-Kv7.1 and anti-Na+/K+-ATPase densitometries. (n = 4) 
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Figure 4.5 Coexpressing WT- and R231H-Kv7.1 increases IKv7.1 when 
measured using an atrial AP waveform at physiological temperature. A. 
Shown are representative IKv7.1 traces from cells expressing WT-Kv7.1 (WT, 
black line, n = 10) or WT- and R231H-Kv7.1 (WT & R231H, blue line, n = 11) 
recorded using the atrial AP waveform at 37 °C. B. The mean peak IKv7.1 (± SE) 
measured during the plateau phase of the atrial AP is plotted in the bar graph (* p 
< 0.05). 
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Figure 4.6 R231H-Kv7.1 is predicted to shorten the atrial AP duration. A. 
Shown is a computation model of an atrial AP waveform at a cycle length of 1000 
ms (indicated by the arrow, Figure 4.6B) for simulations involving control IKs 
(black trace), a mutation increasing the open probability of IKs by 6.25% (R231H-
Kv7.1, blue trace), and a mutation causing a loss-of-function in IKs (red trace). B. 
Plotted is the steady-state AP duration to 90% repolarization (APD90) as a 
function of cycle length for atrial AP simulations with control IKs (black squares), a 
mutation causing an increase in 6.25% open probability (R231H-Kv7.1, blue 
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open triangles), and a loss-of-function of IKs (open red circles). (These data were 
obtained in collaboration with Dr. Don E. Burgess) 
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Figure 4.7 Coexpression of R231H-Kv7.1 and KCNE3 decreases maximally 
activated IKv7.1. A. Shown are representative IKv7.1 from cells expressing KCNE3 
with WT-Kv7.1 (WT & KCNE3, black squares, n = 17) or R231H-Kv7.1 (R231H & 
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KCNE3, blue triangles, n = 18) recorded from the voltage protocol situated above. 
Tail IKv7.1 are enlarged in the inset (scale bars represent 0.2 nA and 10 ms). 
Mean peak step (B) and tail (C) IKv7.1 are plotted as a function of the step pulse 
potential for cells expressing KCNE3 and WT-Kv7.1 or R231H-Kv7.1. Mean peak 
tail IKv7.1 were measured at the initiation of the tail pulse and were described 
using a Boltzmann equation (gray line, Figure 4.7C). The Boltzmann equation 
calculated the mean IMIN (D), IMAX (E), V½ (F), and slope factor, k (G).  (* p < 0.05 
vs. cells expressing WT-Kv7.1)   
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Figure 4.8 Analysis of AF-linked KCNQ1 mutations. A. Representative 
families of IKv7.1 measured from cells expressing KCNE1 and WT-Kv7.1 (WT, 
black squares, n = 14), WT- and S140G-Kv7.1 (WT & S140G, wine open circles, 
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n = 15), WT- and V141M-Kv7.1 (WT & V141M, green diamond, n = 9), WT- and 
R231C-Kv7.1 (WT & R231C, red triangles, n = 11), or WT- and R231H-Kv7.1 
(WT & R231H, blue open triangles, n = 10). Mean peak step (B) and tail (C) IKv7.1 
are plotted as a function of the step pulse potential for cells expressing WT-Kv7.1, 
WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1 or WT- 
and R231H-Kv7.1. Mean peak tail IKv7.1 were measured at the initiation of the tail 
pulse and were described using a Boltzmann equation (gray line, Figure 4.8C). 
The Boltzmann equation calculated the mean IMIN (D), IMAX (E), V½ (F), and slope 
factor, k (G).  (* p < 0.05 vs. cells expressing WT-Kv7.1 or otherwise labeled 
comparisons) 
 
 
 
 
 
 
 
 
 
Copyright © Daniel C. Bartos 2013  
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Chapter 5  
PKA insensitive Kv7.1 mutants identify with latent type 1 long QT 
syndrome 
 
5.1 Introduction 
 The diagnosis of LQTS can be difficult to assess due to the estimation that up 
to 40% of patients genotype positive for LQTS related mutations have a normal 
to borderline resting QTc interval, referred to as concealed LQTS.53, 135 In recent 
years, clinical diagnostic tools (exercise or epinephrine stress testing) have been 
used to unmask latent LQTS phenotypes in patients with concealed LQTS 
(otherwise known as latent LQTS). These diagnostic tools are useful for 
distinguishing between susceptible and ostensibly normal patients. Notably, 
exercise treadmill stress testing reliably predicts latent LQT1.53 Latent LQT1 
patients have QTc intervals that do not shorten during peak exercise, and their 
QTc intervals show abnormal prolongation during the recovery phase after 
exercise. 
 During exercise, elevated levels of epinephrine and norepinephrine activate 
β-adrenergic receptors to increase IKs to regulate the ventricular AP duration.73, 83, 
136 β-adrenergic receptor activation increases IKs by stimulating PKA 
phosphorylation of Kv7.1 at S27. The PKA-induced increase in IKs requires the 
IKs-macromolecular complex, which includes KCNE1 and AKAP9.83, 137 The 
important role that IKs has in regulating the AP duration with exercise is 
exemplified as most LQT1-related events are triggered in patients exercising or 
swimming.138, 139 Studies recently suggest that LQT1 mutations which prevent the 
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PKA-induced increase in IKs might associate with a high-risk for life threatening 
events.83, 91, 92  
 In this chapter, we focus on the LQT1-linked mutation p.Iso235Asn (I235N-
Kv7.1) because we found ten out of ten patients with I235N-Kv7.1 tested positive 
for latent LQT1.140 This suggests that I235N-Kv7.1 confers a high-risk for latent 
LQT1. Each patient has a normal resting QTc interval, but showed exaggerated 
QTc interval prolongation during the recovery period after exercise. I tested the 
hypothesis that I235N-Kv7.1 primarily causes latent LQT1 by generating 
relatively normally functioning Kv7.1 channels that are resistant to PKA 
stimulation.  
 
5.2 Results 
5.2.1 Patients genotype positive for I235N-Kv7.1 have latent LQT1 
 A reliable way to identify patients with LQT1 is to perform ECG exercise 
treadmill stress testing.53 A probable diagnosis of latent LQT1 can be determined 
by calculating the difference between the baseline or resting QTc interval and the 
QTc interval measured at 3 minutes during the recovery phase (ΔQTc). If the 
ΔQTc is ≥ 30 ms, a pregenetic probability for identifying a mutation in KCNQ1 is 
75%.53 Ten members of a large LQT1 family genotype positive for I235N-Kv7.1 
whom underwent treadmill stress testing were analyzed (Figure 5.1A). All ten 
patients had a normal resting QTc interval, but subsequent to the stress test had 
a ΔQTc > 30 ms suggesting latent LQT1 (Figure 5.1B). Additionally, QTc interval 
prolongation persisted at all recovery points following the stress test (Figure 
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5.1C). Aside from exaggerated QTc interval prolongation during exercise stress 
testing, the index patient suffered an episode of near drowning (Figure 5.1A, 
IV:8) and her genotype positive father died suddenly (Figure 5.1A, patient III:5). 
The clinical data for the family genotype positive for I235N-Kv7.1 is summarized 
in Table 5.1. 
 
5.2.2 Cells expressing I235N-Kv7.1 largely reduce IKv7.1, but coexpression of WT- 
and I235N-Kv7.1 alleviates the reduction in IMAX  
 Since most LQT1 mutations reduce IMAX, I voltage-clamped cells expressing 
KCNE1 and WT-Kv7.1, I235-Kv7.1, or WT- and I235N-Kv7.1 (Figure 5.2A). IKv7.1 
was recorded by applying the 5-s voltage protocol described previously (Figure 
3.2). The peak IKv7.1 amplitude recorded during the step pulse (Figure 5.2B) or at 
the start of the tail pulse (Figure 5.2C) was plotted as a function of the step pulse 
potential, and the tail IKv7.1 was described with a Boltzmann equation for cells 
expressing WT-Kv7.1 or WT- and I235N-Kv7.1. IKs-like currents were recorded 
from cells expressing WT-Kv7.1. Cells expressing I235N-Kv7.1 generated small, 
outward IKv7.1 that appeared to activate only at very positive potentials and were 
too small to accurately fit with a Boltzmann equation. Coexpression of WT- and 
I235N-Kv7.1 appeared to mostly correct the loss-of-function phenotype: IMAX was 
only reduced by ~ 30% (Figure 5.2D), the V½ was positively shifted by ~ 15 mV 
(Figure 5.2E), and the slope factor (k) was increased by ~ 6 mV/e-fold Δ (Figure 
5.2F). These data suggest that I235N-Kv7.1 causes a severe loss-of-function 
when expressed alone, but when coexpressed with WT-Kv7.1, it does not. 
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Indeed, the coexpression of WT- and I235N-Kv7.1 mostly corrected the I235N-
Kv7.1 dysfunctional phenotype.  
 
5.2.3 Cells coexpressing WT- and I235N-Kv7.1 prevent PKA stimulation of IKv7.1 
and phosphomimetic substitution at S27 does not increase IKv7.1 
 Since all patients genotype positive for I235N-Kv7.1 who underwent exercise 
treadmill stress testing demonstrate latent LQT1, I tested whether I235N-Kv7.1 
generates Kv7.1 channels that are insensitive to PKA stimulation. I coexpressed 
KCNE1 and AKAP9 with WT-Kv7.1 or WT- and I235N-Kv7.1 and recorded IKv7.1 
using a 5-s voltage protocol similar to Figure 3.2 before and after extracellular 
perfusion of forskolin and IBMX (Figure 5.3A). Preliminary data showed this 
cocktail was most effective at raising intracellular cAMP levels and increasing 
IKv7.1 (data not shown). The peak tail IKv7.1 was plotted as a function of the step 
pulse potential for cells expressing WT-Kv7.1 (Figure 5.3B) or WT- and I235N-
Kv7.1 (Figure 5.3C), and the data was described with a Boltzmann equation 
(Figure 5.3D-F). Perfusion of forskolin and IBMX increased the IMAX in cells 
expressing WT-Kv7.1, but it did not increase IKv7.1 recorded from cells 
coexpressing WT- and I235N-Kv7.1 (Figure 5.3D). These data suggest I235N-
Kv7.1 prevents increase of IKv7.1 subsequent to PKA stimulation via perfusion of 
forskolin and IBMX.  
 There are at least two possibilities as to why I235N-Kv7.1 prevents an 
increase of IKv7.1 after PKA stimulation: (1) I235N-Kv7.1 prevents phosphorylation 
of S27 from PKA or (2) I235N-Kv7.1 prevents appropriate conformational 
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changes necessary to increase IKv7.1 after PKA phosphorylation. A recent study 
suggests phosphomimetic substitution of S27D-Kv7.1 can “rescue” a PKA 
insensitive LQT1 mutation that disrupts phosphorylation of S27.91 Therefore, I 
incorporated a mutation that prevents S27 phosphorylation (S27A-Kv7.1) or a 
phosphomimetic substitution (S27D-Kv7.1). Using the same 5-s voltage protocol 
describe previously (Figure 3.2), I recorded IKv7.1 from cells expressing KCNE1 
and AKAP9 with either S27A-Kv7.1 or S27D-Kv7.1, and from cells coexpressing 
S27A- and S27A/I235N-Kv7.1 or S27D- and S27D/I235N-Kv7.1 (Figure 5.4A). 
The mean peak tail IKv7.1 was plotted as a function of the step pulse potential for 
cells expressing S27A-Kv7.1 and S27D-Kv7.1 (Figure 5.4B) or cells 
coexpressing S27A- and S27A/I235N-Kv7.1 and S27D- and S27D/I235N-Kv7.1 
(Figure 5.4C), and a Boltzmann equation was used to describe the data as 
previously described (Figure 3.2). Compared to cells expressing S27A-Kv7.1, 
IMAX recorded from cells expressing S27D-Kv7.1 was larger (Figure 5.4D). Cells 
coexpressing S27D- and S27D/I235N-Kv7.1 did not increase IMAX compared to 
S27A- and S27A/I235N-Kv7.1 cells (Figure 5.4D). Since the phosphomimetic 
substitution did not increase IKv7.1, these data suggest that I235N-Kv7.1 likely 
prevents the downstream conformational changes in Kv7.1 channels that are 
required to increase IKv7.1 after S27 phosphorylation. 
 
5.2.4 Computational simulations suggest IKs insensitivity to PKA likely contributes 
to ventricular AP prolongation during β-adrenergic stimulation 
 To predict how I235N-Kv7.1 might affect the ventricular AP duration over a 
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wide range of cycle-lengths, we performed simulations using a computational 
model of a ventricular AP without or with β-adrenergic stimulation (Figure 5.5A, 
5.5B, respectively).141 To mimic the effects that I235N-Kv7.1 might have on IKs, 
we decreased the IKs amplitude by 30% and made it insensitive to PKA 
stimulation. We compared these simulations with control IKs or simulations that 
simply reduced the IKs component by 30% without altering PKA sensitivity. We 
measured the APD90 at cycle lengths ranging between 0.3 to 1 s to cover a 
range of heart rates from 200 to 60 bpm, respectively. In the absence of to β-
adrenergic stimulation, a 30% reduction in IKs and a 30% reduction in PKA-
insensitive IKs resulted in only a 1-2% prolongation of the APD90 over the range 
of cycle lengths (Figure 5.5A). Including β-adrenergic in the simulations caused a 
similar increase in the APD90 when the IKs component was reduced by 30%, but 
reducing the IKs component by 30% and making it insensitive to PKA caused the 
APD90 to increase by 6% to 10% over cycle lengths ranging from 0.3 to 1 s 
(Figure 5.5B). These computational simulations suggest that the PKA 
insensitivity of IKs is a critical determinant of ventricular AP duration, especially 
with slower heart rates during β-adrenergic activation. 
 
5.3 Discussion 
 In this chapter, we identified patients genotype positive for I235N-Kv7.1, 
whereby ten out of ten patients had a normal QTc interval at rest, but abnormal 
QTc interval prolongation was unmasked following ECG exercise treadmill stress 
testing. This suggested that I235N-Kv7.1 might cause latent LQT1. Therefore, I 
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directly evaluated the functional properties of I235N-Kv7.1 with or without PKA 
stimulation.  
 Cells coexpressing WT- and I235N-Kv7.1 showed a relatively mild 
dysfunctional phenotype in basal conditions, but did not increase IMAX in 
response to PKA stimulation. These results suggested I235N-Kv7.1 generates 
PKA-insensitive channels (Figures 5.3). Studies show that β-adrenergic 
stimulation increases IKv7.1 by PKA phosphorylation at S27, and phosphomimetic 
substitution can to mimic the functional increase in IKv7.1.83, 137 A recent study 
shows an LQT1 mutation (A341V-Kv7.1) generates PKA-insensitive IKv7.1 by 
decreasing S27 phosphorylation and phosphomimetic substitution at S27 
increases the function of A341V-Kv7.1.91 Contrary to this study, I determined that 
phosphomimetic substitution in I235N-Kv7.1 did not increase the mutant channel 
function (Figure 5.4). Therefore, the PKA-insensitivity of I235N-Kv7.1 is likely 
secondary to a restriction in the conformational changes necessary to increase 
IKv7.1 after S27 is phosphorylated. Incorporating the functional effects of I235N-
Kv7.1 on the IKs component of a ventricular AP computational simulation showed 
AP prolongation primarily occurred during β-adrenergic stimulation, and this was 
exaggerated at slower cycle lengths (Figure 5.5). Together, these data are the 
first to identify a molecular mechanism for latent LQT1; whereas, KCNQ1 
mutations that cause a mild reduction in IMAX in basal conditions and IMAX does 
not increase after PKA activation heighten the risk for latent LQT1. 
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Figure 5.1 Patients genotype positive for I235N-Kv7.1 demonstrate 
exaggerated QTc prolongation following exercise treadmill stress testing. 
A. Shown is a pedigree of a LQT1 family with I235N-Kv7.1 whom underwent 
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ECG treadmill stress testing. Individual males or females are represented as 
squares or circles, respectively; each generation is denoted by a Roman 
numeral; OC denotes an obligate carrier; and the asterisks signify individuals that 
underwent ECG treadmill stress testing. B. The QTc intervals recorded at 
baseline and after 3 minutes recovery used to calculate the ΔQTc of the ten 
patients positive for I235N-Kv7.1 whom underwent ECG treadmill stress testing 
are plotted. C. The mean QTc intervals recorded during the stress test were 
plotted at baseline, peak exercise, and 1, 2, 3, 4, or 5 minutes during recovery. (* 
p < 0.05 vs. baseline)  
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Figure 5.2 The loss-of-function caused by I235N-Kv7.1 is mostly corrected 
by coexpression of WT-Kv7.1. A. Representative families of whole-cell IKv7.1 
measured from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, n = 
11), I235N-Kv7.1 (I235N, red circles, n = 8), or WT- and I235N-Kv7.1 (WT & 
I235N, red triangles, n = 12). IKv7.1 was recorded by applying the 5-s voltage 
protocol previously described. Mean peak step (B) and tail (C) IKv7.1 are plotted 
as a function of the step pulse potential for cells expressing WT-Kv7.1, I235N-
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Kv7.1, or WT- and I235N-Kv7.1. Peak tail IKv7.1 were measured at the initiation of 
the tail pulse and the tail I-V relations were described using a Boltzmann 
equation for cells expressing WT-Kv7.1 or WT- and I235N-Kv7.1 (gray line, 
Figure 5.2C). The Boltzmann equation calculated the mean IMAX (D), V½ (E), and 
slope factor, k (F).  (* p < 0.05 vs. cells expressing WT-Kv7.1) 
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Figure 5.3 IKv7.1 recorded from cells coexpressing WT- and I235N-Kv7.1 is 
insensitive to PKA stimulation. A. Representative traces of IKv7.1 measured 
from cells expressing KCNE1 and AKAP9 with WT-Kv7.1 (WT, n = 6) or WT- and 
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I235N-Kv7.1 (WT & I235N, n = 6) before and after extracellular perfusion of 10 
µM forskolin and 0.2 mM IBMX are shown. IKv7.1 was recorded by applying step 
pulse from -80 to 80 mV in 20-mV increments for 5 s, followed by a tail pulse to -
50 mV for 5 s. The voltage protocol is display in the inset. The mean peak tail 
IKv7.1 are plotted as a function of the step pulse potential for cells expressing (B) 
WT-Kv7.1 before (black squares) and after (black open squares) perfusion or (C) 
WT- and I235N-Kv7.1 before (red triangles) and after (red open triangles) 
perfusion. The peak tail I-V relations for cells expressing WT-Kv7.1 or WT- and 
I235N-Kv7.1 were described using a Boltzmann equation (gray line, Figure 5.3B-
C) to calculate the IMAX (D), V½ (E), and k (F). (* p < 0.05 vs. before perfusion)  
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Figure 5.4 Phosphomimetic substitution of S27D does not increase IKv7.1 for 
I235N-Kv7.1. A. Representative traces of whole-cell IKv7.1 measured from cells 
expressing KCNE1 and AKAP9 with S27A-Kv7.1 (S27A, black squares, n = 5), 
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S27D-Kv7.1 (S27D, black open squares, n = 5), S27A- and S27A/I235N-Kv7.1 
(S27A & S27A/I235N, red triangles, n = 7), or S27D- and S27D/I235N-Kv7.1 
(S27D & S27D/I235N, red open triangles, n = 9) are displayed. IKv7.1 was 
recorded by applying the 5-s voltage protocol previously described. The mean 
peak tail IKv7.1 are plotted as a function of the step pulse potential for cells 
expressing (B) S27A-Kv7.1 or S27D-Kv7.1 and (C) S27A- and S27A/I235N-
Kv7.1 or S27D- and S27D/I235N-Kv7.1. The peak tail I-V relations were 
described using a Boltzmann equation (gray line, Figure 5.3B-C) to calculate the 
IMAX (D), V½ (E), and k (F). (* p < 0.05 vs. S27A)  
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Figure 5.5 Computational simulations of ventricular AP with or without β-
adrenergic stimulation. Computational simulations of a rabbit ventricular for 
control IKs (black squares), IKs reduced by 30% (blue circles), or IKs reduced by 
30% and insensitive to PKA stimulation (red triangles). The APD90 is plotted as a 
function of cycle length in basal conditions (A) or with simulating β-adrenergic 
stimulation (B). C. The corresponding ventricular AP waveform and IKs density is 
displayed. Black traces represent control IKs, blue traces represent simulations in 
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which the IKs component was reduced by 30%, and red traces represent 
simulations in which the IKs component was reduced by 30% and was also 
insensitive to PKA stimulation. (These data were obtained in collaboration with Dr. 
Don E. Burgess) 
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Table 5.1 Clinical characteristics of patients genotype positive for I235N-
Kv7.1 
I235N-Kv7.1 patient data  
Genotype positive subjects, n (female, n) 15 (6) 
ECG treadmill stress test, n (female, n) 10 (3) 
Mean age ± SD (years) 38 ± 14 
Female mean age ± SD (years) 46 ± 19 
Male mean age ± SD (years) 35 ± 11 
Mean resting QTc ± SD (ms) 445 ± 16 
Female mean resting QTc ± SD (ms) 441 ± 24 
Male mean resting QTc ± SD (ms) 446 ± 14 
Mean ΔQTc ± SD (ms) 76 ± 29 
Female mean ΔQTc ± SD (ms) 88 ± 40 
Male mean ΔQTc ± SD (ms) 71 ± 25 
Near drowning episode, n (female, n) 1 (1) 
Sudden cardiac death, n (female, n) 1 (0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Daniel C. Bartos 2013  
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Chapter 6 
General Discussion 
 
6.1 Overall significance 
 Over the past 15 years, KCNQ1 mutations that alter normal Kv7.1 function 
have been linked to congenital arrhythmia syndromes. Most commonly, loss-of-
function KCNQ1 mutations associate with LQT1 and are functionally defined as 
haploinsufficient, dominant-negative, or dominant-negative and PKA-
insensitive.17, 91, 142, 143 Defining these mutations as loss-of-function is a helpful 
way to link a functional phenotype with a clinical phenotype, but LQT1 has 
incomplete penetrance and it does not satisfactorily explain patients with 
pleiotropic or latent phenotypes.43 My findings indicate that the functional 
phenotypes are more complex and the loss-of-function definition is an 
oversimplification. I suspect that refining the categorization of LQT1 classification 
to include multiple functional phenotypes could improve patient management.  
 I have identified two distinct LQT1-associated functional phenotypes: 1) a 
pleiotropic phenotype capable of causing multiple arrhythmia syndromes, and 2) 
a phenotype that causes a relatively benign functional phenotype, but primarily is 
insensitive to PKA stimulation. My data show that the maximally activated tail 
IKv7.1 (IMAX) and PKA sensitivity of mutant Kv7.1 channels (when coexpressed 
with WT-Kv7.1) correlates to mutation-specific differences in LQT1 patient 
phenotypes. Although a gap remains between a genotype positive result and 
complete penetrance, these findings progress our understanding of Kv7.1’s role 
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(and its gene, KCNQ1) in cardiac repolarization and monogenic arrhythmia 
syndromes.  
 
6.2 KCNQ1 mutations associated with a mixed clinical phenotype of long QT 
syndrome and atrial fibrillation  
 With the important finding that there is a 20-fold higher prevalence of AF in 
patients with LQTS compared to the general population comes the question: How 
is this possible?70 Consistent with these observations and my own, studies show 
the degree of QTc interval prolongation varies among patients genotype positive 
for AF-linked gain-of-function KCNQ1 mutations.63-65, 111, 126, 133  
 Interestingly, QTc interval prolongation has long been observed in patients 
diagnosed with AF, but a debate over this issue has ensued because 
determining the QTc interval in a patient with AF is difficult.144 On an ECG, the 
QT interval is directly influenced by the duration of the preceding heart beat 
(ventricular AP duration) and the heart rate.145, 146 This means that a change in 
AP duration causes an immediate adjustment in the QT interval and the 
subsequent QT intervals will also be affected by a new prevailing heart rate.144 
Therefore, determining the QTc interval in a patient who has AF is difficult to 
assess because of the irregularities in time between each successive beat and 
the variations in their heart rate.  
 The coexistence of LQT1 and AF is surprising because of the distinct 
classification of LQT1- or AF-linked KCNQ1 mutations as a loss- or gain-of-
function, respectively. My work has revealed functional phenotypes to distinguish 
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why some LQT1-linked KCNQ1 mutations associate with a higher-risk for 
development of AF. In chapters 3 and 4, I analyzed two mutations of the same 
conserved arginine residue in the Kv7.1 S4 transmembrane segment, R231C-
Kv7.1 and R231H-Kv7.1, and other gain-of-function AF-linked KCNQ1 mutations 
(S140G-Kv7.1 and V141M-Kv7.1). I found R231H-Kv7.1 is the only mutation that 
does not reduce IMAX when coexpressed with WT-Kv7.1 (Figure 4.8C). This is 
somewhat contradictory to what has previously been published for S140G-Kv7.1 
and V141M-Kv7.1.63, 64 Studies suggest that both of these mutations cause a 
gain-of-function when coexpressed with WT-Kv7.1. However, these studies use 
voltage protocols that utilized shorter depolarizing step pulses. I re-plotted the 
peak step IKv7.1 as a function of the step pulse potential at the 1-s (Figure 6.1A) 
and 2-s (Figure 6.1B) time points for cells expressing KCNE1 with WT-Kv7.1, 
WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1, or WT- 
and R231H-Kv7.1. At 1-s, cells coexpressing WT-Kv7.1 and mutant Kv7.1 all 
increased IKv7.1 at positive potentials (Figure 6.1C). At 2-s, cells coexpressing 
WT-Kv7.1 and mutant Kv7.1 were larger at most potentials (Figure 6.1D). 
However, at the 5-s time point, cells coexpressing WT-Kv7.1 and mutant Kv7.1 
did not conduct larger IKv7.1 when compared to cells expressing WT-Kv7.1. In fact, 
a reduction in IKv7.1 was observed from cells coexpressing WT- and V141M-Kv7.1 
or R231C-Kv7.1 at potentials of 50-70 mV (Figure 6.1E). This highlights the 
problem associated with a gain-of-function versus loss-of-function categorization, 
because it depends on the voltage protocol or expression systems used to 
measure IKv7.1.  
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  My data suggest measuring the peak tail IKv7.1 after approaching a stead-
state of maximal activation is reliable in equating functional and clinical 
phenotypes. If we review the clinical data for families genotype positive for 
S140G-Kv7.1, V141M-Kv7.1, R231C-Kv7.1, or R231H-Kv7.1 (Table 6.1), we can 
see that all are linked to AF and all increase constitutive activation of IKv7.1.63, 64, 
111 My data suggest constitutive IKv7.1 at negative potentials is an important 
determinant for AF susceptibility and likely contributes to atrial AP shortening and 
reduced atrial refractoriness. For families genotype positive of either S140G-
Kv7.1 or R231C-Kv7.1, the observation of a prolonged QTc interval in 56 or 44% 
of patients, respectively, is also observed. Consistent with this, coexpressing 
WT-Kv7.1 and S140G-Kv7.1 or R231C-Kv7.1 reduced tail IMAX when compared 
to cells expressing WT-Kv7.1. Importantly, the majority of patients genotype 
positive for R231H-Kv7.1 (86%) have normal QTc intervals and coexpression of 
WT- and R231H-Kv7.1 does not reduce tail IMAX. Furthermore, R231H-Kv7.1 was 
the only mutation that is linked to familial cases of early-onset AF in multiple 
unrelated families suggesting that R231H-Kv7.1 causes a higher-risk functional 
phenotype for AF susceptibility.  
 
6.3 Recent discoveries of patients genotype positive for R231C-Kv7.1 and 
importance for understanding pleiotropic mutations 
 R231C-Kv7.1 was originally reported in patients with severe LQT1, and we 
later identified five additional families with R231C-Kv7.1 that have a family-
specific risk to either LQT1 or AF.105, 111 Since my previous report, more families 
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genotype positive for R231C-Kv7.1 with LQT1 and/or AF have been identified.147, 
148 R231C-Kv7.1 was identified in a girl and was diagnosed with LQT1 and early-
onset AF, and two other family members genotype positive for R231C-Kv7.1 
have a history of LQTS.147 The second report identified two families genotype 
positive for R231C-Kv7.1 with a history of LQT1 and/or AF.148 The first family 
revealed two female R231C-Kv7.1 patients with LQT1, whereby in the latter 
family, six patients were genotype positive for R231C-Kv7.1. The mother has 
LQT1 and early-onset AF, one patient has early-onset AF, and three additional 
patients had a history of LQT1 or sudden cardiac death.148  
 It is clear that patients with the R231C-Kv7.1 mutation present with variable 
clinical phenotypes of LQT1 and/or AF. These new discoveries support my 
findings that a distinct functional phenotype predisposes R231C-Kv7.1 patients to 
both LQT1 and AF; whereas, the constitutive IKv7.1 predisposes patients to AF 
and the decrease in tail IMAX increases the risk of LQT1.111 
 Including R231C-Kv7.1, we have discussed three KCNQ1 mutations linked to 
QTc interval prolongation and AF thus far, and most likely, as genetic testing 
continues more mutations will be associated with both arrhythmia syndromes.63, 
126 A problem arises for pharmacological treatments of these patients because 
drug therapy for AF is contraindicated in patients with a prolonged QTc 
interval.149-151 Several drugs used for AF actually can induce QTc interval 
prolongation and further increase the risk of torsades de pointes in LQT1 
patients.34 Therefore, unique pleiotropic mutations capable of causing multiple 
arrhythmia syndromes like these should be thoroughly evaluated in the future to 
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direct the appropriate intervention in patients with multiple arrhythmia syndromes 
associated to different functional phenotypes.  
 Although R231C-Kv7.1 is the first KCNQ1 mutation described to be capable 
of pleiotropic expression, this observation is also linked to individual mutations in 
genes encoding several other ion channels. Particularly, mutations in SNC5A 
(which encodes Nav1.5) associate with overlapping clinical phenotypes such as 
LQT3 or Brugada syndrome. These mutations generate a mixed functional 
phenotype causing impairments in inactivation that increase late INa similar to 
LQT3-linked SCN5A mutations, but also reduce overall Nav channel availability 
comparably to Brugada-linked mutations.152-154 A study suggests that even 
mutations in adapter protein genes, such as ANK2, can be causative of multiple 
arrhythmia syndromes (LQT4, bradycardia, and AF) in a single family by 
disrupting localization of Na+/K+-ATPase and/or Na+/Ca2+ exchanger.96 In 
combination with my work, these studies emphasize that the complex nature of 
channelopathies can be unpredictable. Relating the pleiotropic functional 
phenotypes of mutations associated to multiple arrhythmia syndromes can 
improve the therapeutic management in these patients.  
 
6.4 Exercise treadmill stress testing correlates clinical observations with a 
molecular mechanism 
 Recent studies analyzing data from the International LQTS registry and 
functional studies suggest PKA-insensitive LQT1 mutations increase the risk for 
life-threatening events compared to other transmembrane LQT1 mutations that 
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respond to PKA stimulation.91, 92, 155 These studies also imply patients with PKA-
insensitive LQT1 mutations might benefit more with β-blocker therapy. 
Regardless, patients identified with clinically proven LQT1 mutations that fail to 
manifest any obvious clinical symptoms (latent LQT1) are hard to treat, and 
molecular mechanisms that underlie a latent LQT1 phenotype have yet to be 
determined.156 Furthermore, studies show that genotype positive individuals with 
concealed LQTS still have a > 10-fold relative risk of sudden cardiac death than 
genotype-negative family members.157 A reliable comprehensive approach is 
needed to accurately predict mutation-specific risks associated with patients that 
are genotype positive for LQT1-linked mutations to better treat patients with 
elevated susceptibility to arrhythmogenic events. We propose a method (ECG 
treadmill stress testing) to reveal latent LQT1 phenotypes in families with 
concealed LQT1 and assess a mutation-specific risk for this elusive subtype of 
LQT1. 
 A non-invasive clinical tool to assess the QTc interval response to β-
adrenergic activation is the ECG exercise treadmill stress test. Specifically, 
measuring QTc intervals during the recovery phase following treadmill testing is a 
reliable method for pre-genetically distinguishing LQT1 patients from control or 
other LQTS types.53 Using this clinical tool, we identified a large, 
multigenerational family genotype positive for I235N-Kv7.1 and all ten patients 
whom underwent treadmill stress testing met the criteria for latent LQT1. 
Functional analyses showed I235N-Kv7.1 caused a severe loss-of-function 
phenotype, but coexpression of WT- and I235N-Kv7.1 mostly restored normal 
   104 
function (Figure 5.2). These data suggest that I235N-Kv7.1 does not cause 
dominant negative suppression of IKv7.1 and contradict functional studies 
performed in Xenopus laevis oocytes.158 We suspect discrepancies between our 
studies might be due to the expression system used, and previous studies have 
highlighted problems with interpreting functional properties of LQTS mutations in 
Xenopus laevis oocytes.159, 160 
 More importantly, further functional analyses suggested that cells 
coexpressing WT- and I235N-Kv7.1 conducted IKv7.1 that were insensitive to PKA 
stimulation following perfusion of forskolin and IBMX (Figure 5.3). A recent study 
shows that a dominant-negative PKA-insensitive LQT1 mutation (A341V-Kv7.1) 
reduces Kv7.1 phosphorylation following PKA stimulation, and prevents a 
functional increase in IKv7.1.91 The functional increase of IKv7.1 from cells 
expressing A341V-Kv7.1 is rescued by phosphomimetic substitution, which 
further supports the initial concept that this mutation prevented Kv7.1 from being 
phosphorylated.91 My data suggest that the relatively benign I235N-Kv7.1 
disrupts PKA-sensitivity by restricting conformational changes necessary to 
increase IKv7.1 following PKA stimulation because phosphomimetic substitution 
did not increase IKv7.1 (Figure 5.4). These results might explain why patients 
genotype positive for I235N-Kv7.1 have a normal QTc interval at rest, but, 
exaggerated QTc interval prolongation persists following β-adrenergic stimulation 
(exercise treadmill stress testing).  
 In addition to exercise treadmill stress testing, measuring patient-specific 
differences in autonomic reflexes may also be used to identify high-risk LQT1 
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patients.161, 162 LQT1 patients who are at a higher risk for experiencing symptoms 
have a faster decline in heart rate within the first minute after cessation of a 
bicycle ergometer exercise stress test.162 Similar, our use of exercise treadmill 
stress testing also focuses on time points during the recovery phase, where 
exaggerated QTc interval prolongation is noted.53 Both stress tests imply the 
importance of IKs in regulating ventricular AP duration within seconds to minutes 
following the conclusion of exercise testing. During recovery, powerful vagal 
reflexes work to slow the heart rate, but sympathoadrenal signaling (circulating 
levels of epinephrine and norepinephrine) remains elevated.163, 164 This means 
that as the heart rate slows, β-adrenergic receptors are still activated. 
Remarkably, our computational simulations of a ventricular AP shows that 
including the functional effects of I235N-Kv7.1 in the IKs component primarily 
cause AP prolongation with β-adrenergic stimulation, and AP prolongation is 
exaggerated at slower cycle lengths (Figure 5.5). These data suggest that 
exercise stress testing might be useful for identifying patients with KCNQ1 
mutations that generate PKA-insensitive Kv7.1 channels, and patients with latent 
LQT1 may benefit more from β-blocker therapy than other symptomatic patients.  
 PKA-insensitive mutant Kv7.1 channels are being increasingly linked as a risk 
factor of symptoms, and a noninvasive technique to assess these issues is 
needed.83, 92, 115 The first LQT1 mutation shown to decrease PKA-sensitivity of 
IKv7.1 was a mutation within the leucine zipper motif of Kv7.1, G589D-Kv7.1, and 
this mutation disrupted AKAP9 from binding to C-terminus of Kv7.1.83 Additionally, 
a missense mutation in the gene encoding AKAP9 is associated with LQT11 and 
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similarly causes a reduction in the interaction between Kv7.1 and AKAP9.90 As 
mentioned, a mutation in the Kv7.1 S6 transmembrane segment, A341V-Kv7.1, 
was shown to generate PKA-insensitive Kv7.1 channels by preventing PKA 
phosphorylation at S27.91 Most recently, several LQT1 mutations located in the 
cytoplasmic loops linking S2-S3 or S4-S5 transmembrane segments were shown 
to be resistant to PKA stimulation by forskolin.92 Although in chapter 4, I 
suggested that R231H-Kv7.1 does not cause a loss-of-function phenotype similar 
to LQT1 mutations and has a high propensity to cause AF, several patients had 
borderline QTc intervals or epinephrine induced QTc prolongation suggesting 
ventricular abnormalities.128 Utilizing a similar approach, I tested whether R231H-
Kv7.1 prevented PKA-induced increase of IKv7.1 from cells coexpressing R231H-
Kv7.1 (KCNE1 and AKAP9 were also coexpressed). As expected, PKA 
stimulation increased the mean peak tail IKv7.1 in cells expressing WT-Kv7.1 by 
almost 2-fold (Figure 6.2B), but Cells expressing R231H-Kv7.1 did not (Figure 
6.2B). These data suggest that R231H-Kv7.1 might also suppress PKA 
stimulation of IKv7.1. I have now shown two mutations, both located in the Kv7.1 
S4 transmembrane segments (R231H-Kv7.1 and I235N-Kv7.1) to be insensitive 
to PKA stimulation, which is evidence to predict that more KCNQ1 mutations 
located in the transmembrane regions of Kv7.1 will be PKA-insensitive.126  
 Together, these data propose that exercise treadmill stress testing (and 
possibly epinephrine testing) might aid in revealing mutations that cause PKA-
insensitive Kv7.1 channels in patients with latent LQT1. To the best of my 
knowledge these are the first data to link PKA-insensitivity to an abnormal ECG 
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exercise stress test. Whether or not KCNQ1 mutations commonly generate PKA-
insensitive Kv7.1 channels warrants further investigation. These findings 
represent a significant breakthrough in correlating the predictive value of a non-
invasive clinical technique with molecular mechanisms/functional phenotypes of 
LQT1 mutations. Future testing incorporating exercise treadmill stress testing in 
combination with mutation-specific risk assessment can improve individual LQT1 
patient treatment. 
 
6.5 Kv7.1 voltage sensor mutations  
 In this dissertation, I studied the functional properties of three mutations 
located within the Kv7.1 voltage-sensing S4 transmembrane segment (R231C-
Kv7.1, R231H-Kv7.1, and I235N-Kv7.1) that are associated with three different 
clinical characteristics. Cells expressing these mutant Kv7.1 channels with 
KCNE1 all alter voltage dependence of activation when compared to WT-Kv7.1 
expressing cells, but do so by generating three distinct functional phenotypes: 1) 
large constitutive IKv7.1, 2) constitutive IKv7.1 of similar tail IMAX, and 3) positive shift 
in voltage dependence of activation. This is interesting because two of these 
mutations alter the same residue (R231) and the third mutation is only four amino 
acid residues downstream (I235).  
 Several studies show LQT1 mutations located in the Kv7.1 S4 
transmembrane segment reduce IKv7.1, slow the time course of activation, or 
cause a positive shift in the voltage dependence of activation, similar to I235N-
Kv7.1.110, 158, 165, 166 Aside from the voltage sensor, a report shows three LQT1-
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linked Kv7.1 mutations located in a region critical for cell surface expression and 
within close proximity to one another cause variable dysfunction and surface 
expression of Kv7.1.169 In the neuronally expressed Kv7.2 channel, two 
mutations of the same conserved arginine residue in S4 associate with benign or 
severe forms of neonatal-onset encephalopathies. Both of these mutations cause 
a positive shift in the voltage dependence of activation and increase the time 
course of deactivation of Kv7.2 to variable degrees, suggesting a variable 
predisposition to severity of disease, similar to R231C-Kv7.1 and R231H-
Kv7.1.167 Furthermore, our lab shows that mutations linked to LQT2 in the Kv11.1 
S4 conserved arginine residues that are only three residues apart also cause 
variable gating abnormalities or cell surface expression of Kv11.1.168  
 Mutations of specific charged amino acid residues of the S4 transmembrane 
segment are not isolated to Kv channels. S4 mutations of Nav1.1 are linked to 
congenital cases of epilepsy and cause a gain-of-function phenotype by 
destabilizing inactivation and increasing persistent INa similar to LQT3-related 
Nav1.5 mutations.170 In Nav1.4 channels, similar S4 gain-of-function mutations 
are associated with paramyotonia by destabilizing inactivation and slowing the 
time course of deactivation.171, 172 Also, Cav2.1 gain-of-function S4 mutations 
increase the open probability and channel density to cause an increased risk of 
hemiplegic migraines.173, 174 
 Together, these studies suggest that S4 voltage-sensing mutations continue 
to be a hot spot for disrupting gating properties of voltage-gated ion channels. 
Furthermore, they show the proximity of an amino acid residue to a known 
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mutation is not sufficient to predict functional phenotypes. The association of 
mutations within the S4 voltage-sensing domain with severe clinical phenotypes 
highlights the consequence that disrupting important charges critical for sensing 
changes in membrane potentials has in proper gating and channel function. 
 
6.6 Concluding statement 
 The simple binary definition of a gain-of-function versus loss-of-function 
mutation is problematic in determining the risk for disease because a mutation-
specific overlap in clinical phenotypes exists.63, 71, 111, 126 I was able to identify a 
pleiotropic functional phenotype that can explain the overlap in clinical 
phenotypes observed in patients with R231C-Kv7.1 (and possibly S140G-Kv7.1). 
Also, I identified a higher-risk functional phenotype for association with a high 
prevalence of AF for patients genotype positive for R231H-Kv7.1. This suggests 
that analysis of the peak tail IMAX is indicative of whether or not QTc interval 
prolongation will be observed in patients. Also, these data support that the 
presence of constitutive IKv7.1 is increases the risk of reduced atrial refractoriness 
and subsequently AF. Furthermore, in patients with latent LQT1, we directly 
linked a molecular mechanism with a clinical stress test evaluation. I235N-Kv7.1 
generates a benign functional phenotype that is resistant to PKA stimulation and 
increases the risk for exaggerated QTc interval prolongation or latent LQT1 
phenotypes during exercise. The findings and implications of this dissertation 
help determine the role of Kv7.1 in atrial and ventricular AP repolarization by 
directly linking clinical observations with functional data.  
   110 
 
 
6.7 Future Studies 
 Concrete evidence explaining disparity of patient-specific differences that 
influence the prevalence of disease is not yet determined. Results from this 
dissertation using a heterologous expression system can explain possible 
molecular mechanisms of arrhythmia for genotype-positive patients, but it still 
does not clarify why penetrance of these congenital arrhythmia syndromes are 
not 100%. Using heterologous expression systems are very useful in studying 
biophysical properties of LQT1 mutations, however the lack of important auxiliary 
subunits or regulatory proteins does not recapitulate the exact macromolecular 
environment in a human heart. Most often, mouse models are used to study 
congenital cardiovascular diseases, but using transgenic LQT1 mouse models is 
problematic because IKs does not contribute to cardiac repolarization.175 Recent 
developments in techniques to turn human patients’ fibroblasts into inducible 
pluripotent stem cells and then, further differentiate these cells into cardiac-like 
myocytes has excited the fields of congenital disease.176  
 In LQT1, studying the electrical properties of patient-derived cardiac-like 
myocytes might aid in understanding patient-specific differences that affect 
variable penetrance of disease within families carrying the same mutation. 
Several groups have shown that this technique can be useful when studying 
different types of LQTS, including LQT1; whereas, cardiac-like myocytes derived 
from symptomatic genotype-positive patients show anticipated AP prolongation, 
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inducible EADs, and drug sensitive currents.177-180 Studying mutations associated 
with multiple clinical phenotypes such as, R231C-Kv7.1 or R231H-Kv7.1, might 
be beneficial in our understanding of patient-specific risk factors. With consent, 
obtaining samples of symptomatic or asymptomatic mutation carriers as well as 
genotype-negative patients from the families studied or control patients from the 
general population would be an interesting approach to study the electrical 
differences in cardiac-like myocytes. Studying R231C-Kv7.1 or R231H-Kv7.1 
provides an additional value because not only are there differences within a 
single family, rather both mutations are found in multiple unrelated families that 
associate to family-specific clinical phenotypes as well. Cells derived from 
patients genotype positive for I235N-Kv7.1 or other mutations causative of the 
latent LQT1 phenotype might also help understand the role of β-adrenergic 
regulation of Kv7.1 and LQT1-related events. 
 Although encouraging, the technique of using patient-specific inducible 
pluripotent stem cells does have limitations. Upon differentiation, the cardiac-like 
myocytes generated are a milieu of cells with electrophysiological features of 
nodal, atrial, or ventricular myocytes and selectable markers to distinguish cell 
types are needed.181 Also, cardiac-like myocytes have immature 
electrophysiological features that resemble fetal cardiomyocytes, and do not 
express the same proportion of several ion channels or the regulatory proteins in 
macromolecular complexes expressed in the adult human heart.177-184 Lastly, it is 
impossible to account for environmental influence on gene expression, and this 
system obviously cannot recapitulate the events of one individual’s unique 
   112 
development that may alter susceptibility to clinical phenotypes. Nonetheless, 
until we can account for all limitations, the use of patient derived cardiac-like 
myocytes provides a positive initiative to understand patient-specific differences 
in congenital arrhythmia syndromes. 
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Figure 6.1 Analysis of step pulse for AF mutants at 1, 2, and 5 seconds. 
Mean peak step IKv7.1 are plotted as a function of the step pulse potential at 1-s 
(A) or 2-s (B) for cells expressing WT-Kv7.1 (black squares), WT- and S140G-
Kv7.1 (wine open circles), WT- and V141M-Kv7.1 (green diamonds), WT- and 
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R231C-Kv7.1 (red triangles), or WT- and R231H-Kv7.1 (blue open triangles). The 
mean peak step IKv7.1 is shown for the 40, 50, 60, and 70 mV step pulse at 1-s 
(A), 2-s (B), or 5-s (C) time points. (* p < 0.05 vs. cells expressing WT-Kv7.1) 
  
   115 
Figure 6.2 R231H-Kv7.1 is insensitive to PKA stimulation. A. Representative 
IKv7.1 traces of cells coexpressing WT-Kv7.1 (WT & AKAP9, n = 5) or R231H-
Kv7.1 (R231H & AKAP9, n = 5) with KCNE1 and AKAP9 were recorded before 
and after extracellular perfusion of Forskolin and IBMX. IKv7.1 was recorded from 
a holding potential of -80 mV by applying a depolarizing step pulse to 50 mV for 5 
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s followed by a tail pulse to -50 mV for 5 s before and after extracellular perfusion 
of forskolin and IBMX (see inset). B. The bar graph compares the mean peak tail 
IKv7.1 recorded before and after perfusion. (* p < 0.05 vs. before perfusion) 
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TABLE 6.1 Clinical characteristics of families genotype positive for KCNQ1 
mutations linked to early-onset AF  
S140G-Kv7.1 patient data  
Genotype positive S140G families, n 1 
Families with history of LQT1  1 
Families with history of familial AF 1 
Genotype positive subjects, n (female, n) 16 (9) 
Mean QTc ± SD (ms) 453 ± 47 
Female mean QTc ± SD (ms) 451 ± 42 
Male mean QTc ± SD (ms) 456 ± 56 
Prolonged QTc interval, n (female, n) 9 (4) 
Symptomatic, n (female, n) 4 (2) 
Early onset AF, n (female, n) 15 (8) 
V141M-Kv7.1 patient data  
Genotype positive V141M families, n 1 
Families with history of LQT1 0 
Families with history of familial AF 1 
Genotype positive patients, n (female, n) 1 (1) 
Patient QTc (ms) 280 
Prolonged QTc interval, n (female, n) 0 (0) 
Symptomatic, n (female, n) 0 (0) 
Early-onset AF, n (female, n) 1 (1) 
R231C-Kv7.1 patient data  
Genotype positive R231C families, n 6 
Families with history of LQT1  5 
Families with history of familial AF 1 
Genotype positive subjects, n (female, n) 18 (9) 
Mean QTc ± SD (ms) 452 ± 48 
Female mean QTc ± SD (ms) 459 ± 32 
Male mean QTc ± SD (ms) 443 ± 61 
Prolonged QTc interval, n (female, n) 8 (5) 
Symptomatic, n (female, n) 1 (0) 
Early onset AF, n (female, n) 4 (1) 
R231H-Kv7.1 patient data  
Genotype positive R231H families, n 5 
Families with history of LQT1 1 
Families with history of familial AF 4 
Genotype positive patients, n (female, n) 14 (9) 
Mean QTc ± SD (ms) 444 ± 20 
Female mean QTc ± SD (ms) 446 ± 16 
Male mean QTc ± SD (ms) 441 ± 27 
Prolonged QTc interval, n (female, n) 2 (1) 
Symptomatic, n (female, n) 3 (3) 
Early-onset AF, n (female, n) 11 (8) 
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Appendix A.  
Limitations 
 These data were obtained in a widely used heterologous overexpression 
system (HEK293 cells). The endogenous currents and proteins expressed in the 
HEK293 cell system could differ from native myocytes. To reduce the 
interference of endogenous HEK293 cells, the tail pulse was used to distinguish 
differences between current densities because endogenous currents are not 
activated at -50 mV. Also, the desired ratio of protein expression are not exact 
due to the use of transient transfections of multiple DNA plasmids. Therefore, 
control cells expressing WT-Kv7.1 with the appropriate KCNE β-subunit were 
always compared to cells expressing mutant Kv7.1 channels on each occasion of 
data acquisition. The perfusion of forskolin and IBMX could have off-target 
effects that activate other signaling cascades than intended and could induce 
alternative channel regulation. Also, the perfusion itself could have altered 
channel biophysics; therefore, even cells expressing WT-Kv7.1 that did not 
increase IKv7.1 post-perfusion were used in data analysis. The phosphomimetic 
substitution of S27D-Kv7.1 does not mimic phosphorylation of S27 exactly, and 
the results of the substitution could be misleading.  
 Furthermore, families genotype positive for the mutations discussed in this 
dissertation could still be discovered, and additional families most likely will be 
found considering the ease and availability of genetic testing today. Therefore, 
the families discussed could be an “under-assumption” of the true prevalence of 
LQT1, AF, or concealed LQT1 within the general population. Unidentified patient 
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specific differences may also contribute to the different clinical phenotypes 
associated with unrelated families harboring the same mutation.  
 Lastly, the computational models used are in silico simulations and are used 
only for didactic purposes. For β-adrenergic simulations, a rabbit ventricular 
model was used, and electrical properties of a rabbit are not identical to a human. 
Therefore, the mechanisms of arrhythmias proposed by these models could be 
inaccurate in predicting outcomes in a native system.  
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